alicyclic ketone - Ontology Report - Rat Genome Database

Submit Data | Help | Video Tutorials | News | Publications | Download | REST API | Citing RGD | Contact

Advanced Search (OLGA)

CHEBI ONTOLOGY - ANNOTATIONS

{{ watchLinkText }}

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:	alicyclic ketone	go back to main search page
Accession:	CHEBI:36132	browse the term
Definition:	A cyclic ketone in which the carbocyclic ring structure which may be saturated or unsaturated, but may not be a benzenoid or other aromatic system.
Synonyms:	related_synonym:	alicyclic ketones

show annotations for term's descendants Sort by:
Rat (1268) Mouse (1270) Human (1275) Chinchilla (0) Bonobo (0) Dog (1) Squirrel (0) Pig (9) Green Monkey (0) Naked Mole-rat (0) All
Genes (1268)

(+)-beta-thujone

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

acetyl-CoA carboxylase alpha

multiple interactions

[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in decreased expression of ACACA mRNA

NCBI chr10:69,014,261...69,276,453
Ensembl chr10:69,014,170...69,276,457

G

acetyl-CoA carboxylase beta

multiple interactions

[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of ACACB mRNA

NCBI chr12:42,365,800...42,477,651
Ensembl chr12:42,366,548...42,457,655

G

ATP citrate lyase

multiple interactions

[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in decreased expression of ACLY mRNA

NCBI chr10:85,412,045...85,464,253
Ensembl chr10:85,412,049...85,463,320

G

actin alpha 2, smooth muscle

multiple interactions

[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in decreased expression of ACTA2 mRNA

NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554

G

aryl hydrocarbon receptor

multiple interactions

[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of AHR mRNA

NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568

G

AKT serine/threonine kinase 1

multiple interactions

[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of AKT1 mRNA

NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921

G

catalase

multiple interactions

[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in decreased expression of CAT mRNA

NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478

G

cellular communication network factor 2

multiple interactions

[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of CTGF mRNA

NCBI chr 1:20,802,199...20,805,315
Ensembl chr 1:20,802,199...20,805,734

G

cholinergic receptor nicotinic alpha 7 subunit

multiple interactions

beta-thujone inhibits the reaction [Acetylcholine results in increased activity of CHRNA7 protein]; beta-thujone inhibits the reaction [Choline results in increased activity of CHRNA7 protein]

NCBI chr 1:116,711,559...116,837,269
Ensembl chr 1:116,714,711...116,837,240

G

collagen type I alpha 1 chain

multiple interactions

[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in decreased expression of COL1A1 mRNA

NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624

G

carnitine palmitoyltransferase 1A

multiple interactions

[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of CPT1A mRNA

NCBI chr 1:200,564,634...200,627,059
Ensembl chr 1:200,565,613...200,627,055

G

carnitine palmitoyltransferase 2

multiple interactions

[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of CPT2 mRNA

NCBI chr 5:122,664,677...122,682,126
Ensembl chr 5:122,664,677...122,682,095

G

cytochrome P450, family 1, subfamily a, polypeptide 1

multiple interactions

[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of CYP1A1 mRNA

NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125

G

diacylglycerol O-acyltransferase 1

multiple interactions

[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of DGAT1 mRNA

NCBI chr 7:108,223,860...108,235,413
Ensembl chr 7:108,218,524...108,234,299

G

fatty acid synthase

multiple interactions

[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of FASN mRNA

NCBI chr10:106,072,093...106,090,259
Ensembl chr10:106,072,091...106,090,261

G

forkhead box O1

multiple interactions

[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of FOXO1 mRNA

NCBI chr 2:136,312,168...136,390,603
Ensembl chr 2:136,312,168...136,387,790

G

gamma-aminobutyric acid type A receptor subunit alpha 1

multiple interactions

beta-thujone inhibits the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA1 protein binds to GABRB2 protein binds to GABRG2 protein]]

NCBI chr10:26,595,151...26,650,611
Ensembl chr10:26,595,160...26,650,864

G

gamma-aminobutyric acid type A receptor subunit beta 2

multiple interactions

beta-thujone inhibits the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA1 protein binds to GABRB2 protein binds to GABRG2 protein]]

NCBI chr10:26,936,592...27,156,141
Ensembl chr10:26,936,551...27,151,251

G

gamma-aminobutyric acid type A receptor subunit gamma 2

multiple interactions

beta-thujone inhibits the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA1 protein binds to GABRB2 protein binds to GABRG2 protein]]

NCBI chr10:26,374,693...26,463,937
Ensembl chr10:26,374,694...26,464,346

G

glutathione peroxidase 1

multiple interactions

[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of GPX1 mRNA

NCBI chr 8:109,026,905...109,028,031
Ensembl chr 8:109,026,905...109,028,024

G

glutathione-disulfide reductase

multiple interactions

[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of GSR mRNA

NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661

G

malonyl-CoA decarboxylase

multiple interactions

[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of MLYCD mRNA

NCBI chr19:47,447,931...47,463,794
Ensembl chr19:47,447,970...47,463,793

G

NFE2 like bZIP transcription factor 2

multiple interactions

[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of NFE2L2 mRNA

NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737

G

nuclear factor kappa B subunit 1

multiple interactions

[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of NFKB1 mRNA

NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404

G

peroxisome proliferator activated receptor alpha

multiple interactions

[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of PPARA mRNA

NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346

G

prostaglandin-endoperoxide synthase 1

multiple interactions

[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of PTGS1 mRNA

NCBI chr 3:19,584,015...19,605,589
Ensembl chr 3:19,584,015...19,605,586

G

snail family transcriptional repressor 1

multiple interactions

[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of SNAI1 mRNA

NCBI chr 3:156,248,479...156,252,969
Ensembl chr 3:156,248,485...156,252,969

G

superoxide dismutase 1

multiple interactions

[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of SOD1 mRNA

NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249

G

transforming growth factor, beta 1

multiple interactions

[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in decreased expression of TGFB1 mRNA

NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847

G

zinc finger E-box binding homeobox 1

multiple interactions

[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of ZEB1 mRNA

NCBI chr17:51,948,948...52,116,018
Ensembl chr17:51,948,948...52,115,214

G

zinc finger E-box binding homeobox 2

multiple interactions

[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of ZEB2 mRNA

NCBI chr 3:29,214,581...29,344,890
Ensembl chr 3:29,218,301...29,345,157

(R)-camphor

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

acetyl-CoA carboxylase alpha

multiple interactions

[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in decreased expression of ACACA mRNA

NCBI chr10:69,014,261...69,276,453
Ensembl chr10:69,014,170...69,276,457

G

acetyl-CoA carboxylase beta

multiple interactions

[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of ACACB mRNA

NCBI chr12:42,365,800...42,477,651
Ensembl chr12:42,366,548...42,457,655

G

ATP citrate lyase

multiple interactions

[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in decreased expression of ACLY mRNA

NCBI chr10:85,412,045...85,464,253
Ensembl chr10:85,412,049...85,463,320

G

actin alpha 2, smooth muscle

multiple interactions

[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in decreased expression of ACTA2 mRNA

NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554

G

aryl hydrocarbon receptor

multiple interactions

[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of AHR mRNA

NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568

G

AKT serine/threonine kinase 1

multiple interactions

[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of AKT1 mRNA

NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921

G

catalase

multiple interactions

[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in decreased expression of CAT mRNA

NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478

G

cellular communication network factor 2

multiple interactions

[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of CTGF mRNA

NCBI chr 1:20,802,199...20,805,315
Ensembl chr 1:20,802,199...20,805,734

G

collagen type I alpha 1 chain

multiple interactions

[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in decreased expression of COL1A1 mRNA

NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624

G

collagen type I alpha 2 chain

affects expression

Camphor analog affects the expression of COL1A2 mRNA

NCBI chr 4:32,563,938...32,598,868
Ensembl chr 4:32,563,381...32,598,867

G

carnitine palmitoyltransferase 1A

multiple interactions

[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of CPT1A mRNA

NCBI chr 1:200,564,634...200,627,059
Ensembl chr 1:200,565,613...200,627,055

G

carnitine palmitoyltransferase 2

multiple interactions

[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of CPT2 mRNA

NCBI chr 5:122,664,677...122,682,126
Ensembl chr 5:122,664,677...122,682,095

G

cytochrome P450, family 1, subfamily a, polypeptide 1

multiple interactions

[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of CYP1A1 mRNA

NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125

G

cytochrome P450, family 2, subfamily b, polypeptide 1

decreases activity

Camphor results in decreased activity of CYP2B1 protein

NCBI chr 1:81,518,387...81,544,999
Ensembl chr 1:81,518,408...81,542,052

G

cytochrome P450, family 2, subfamily b, polypeptide 3

multiple interactions

Camphor inhibits the reaction [CYP2B6 protein results in increased hydrolysis of Bupropion]

NCBI chr 1:81,652,762...81,732,153
Ensembl chr 1:81,652,787...81,732,143

G

diacylglycerol O-acyltransferase 1

multiple interactions

[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of DGAT1 mRNA

NCBI chr 7:108,223,860...108,235,413
Ensembl chr 7:108,218,524...108,234,299

G

estrogen receptor 1

multiple interactions

Camphor binds to and results in increased activity of ESR1 protein

NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002

G

fatty acid synthase

multiple interactions

[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of FASN mRNA

NCBI chr10:106,072,093...106,090,259
Ensembl chr10:106,072,091...106,090,261

G

forkhead box O1

multiple interactions

[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of FOXO1 mRNA

NCBI chr 2:136,312,168...136,390,603
Ensembl chr 2:136,312,168...136,387,790

G

gamma-aminobutyric acid type A receptor subunit alpha 1

multiple interactions

Camphor promotes the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA1 protein binds to GABRB2 protein binds to GABRG2 protein]]

NCBI chr10:26,595,151...26,650,611
Ensembl chr10:26,595,160...26,650,864

G

gamma-aminobutyric acid type A receptor subunit beta 2

multiple interactions

Camphor promotes the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA1 protein binds to GABRB2 protein binds to GABRG2 protein]]

NCBI chr10:26,936,592...27,156,141
Ensembl chr10:26,936,551...27,151,251

G

gamma-aminobutyric acid type A receptor subunit gamma 2

multiple interactions

Camphor promotes the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA1 protein binds to GABRB2 protein binds to GABRG2 protein]]

NCBI chr10:26,374,693...26,463,937
Ensembl chr10:26,374,694...26,464,346

G

glutathione peroxidase 1

multiple interactions

[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of GPX1 mRNA

NCBI chr 8:109,026,905...109,028,031
Ensembl chr 8:109,026,905...109,028,024

G

glutathione-disulfide reductase

multiple interactions

[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of GSR mRNA

NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661

G

malonyl-CoA decarboxylase

multiple interactions

[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of MLYCD mRNA

NCBI chr19:47,447,931...47,463,794
Ensembl chr19:47,447,970...47,463,793

G

myeloperoxidase

multiple interactions

Camphor inhibits the reaction [cinnamaldehyde results in increased activity of MPO protein]

NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819

G

NFE2 like bZIP transcription factor 2

multiple interactions

[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of NFE2L2 mRNA

NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737

G

nuclear factor kappa B subunit 1

multiple interactions

[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of NFKB1 mRNA

NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404

G

progesterone receptor

multiple interactions

Camphor binds to and results in decreased activity of PGR protein

NCBI chr 8:6,072,673...6,131,552
Ensembl chr 8:6,072,673...6,131,344

G

peroxisome proliferator activated receptor alpha

multiple interactions

[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of PPARA mRNA

NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346

G

prostaglandin-endoperoxide synthase 1

multiple interactions

[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of PTGS1 mRNA

NCBI chr 3:19,584,015...19,605,589
Ensembl chr 3:19,584,015...19,605,586

G

RUNX family transcription factor 2

affects expression

Camphor analog affects the expression of RUNX2 mRNA

NCBI chr 9:16,167,504...16,492,826
Ensembl chr 9:16,167,482...16,492,167

G

snail family transcriptional repressor 1

multiple interactions

[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of SNAI1 mRNA

NCBI chr 3:156,248,479...156,252,969
Ensembl chr 3:156,248,485...156,252,969

G

superoxide dismutase 1

multiple interactions

[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of SOD1 mRNA

NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249

G

secreted protein acidic and cysteine rich

affects expression

Camphor analog affects the expression of SPARC mRNA

NCBI chr10:39,516,394...39,538,252
Ensembl chr10:39,516,406...39,538,396

G

transforming growth factor, beta 1

multiple interactions

[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in decreased expression of TGFB1 mRNA

NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847

G

transient receptor potential cation channel, subfamily V, member 1

multiple interactions

Lidocaine promotes the reaction [Camphor results in increased activity of TRPV1 protein]

NCBI chr10:57,851,428...57,876,513
Ensembl chr10:57,851,428...57,876,513

G

transient receptor potential cation channel, subfamily V, member 3

increases activity
multiple interactions

Camphor results in increased activity of TRPV3 protein
isopentenyl pyrophosphate inhibits the reaction [Camphor results in increased activity of TRPV3 protein]

NCBI chr10:57,883,546...57,915,865
Ensembl chr10:57,883,546...57,913,296

G

zinc finger E-box binding homeobox 1

multiple interactions

[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of ZEB1 mRNA

NCBI chr17:51,948,948...52,116,018
Ensembl chr17:51,948,948...52,115,214

G

zinc finger E-box binding homeobox 2

multiple interactions

[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of ZEB2 mRNA

NCBI chr 3:29,214,581...29,344,890
Ensembl chr 3:29,218,301...29,345,157

13,14-dihydro-15-ketoprostaglandin D2

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

C-X-C motif chemokine ligand 2

increases expression
multiple interactions

13,14-dihydro-15-ketoprostaglandin D2 results in increased expression of CXCL2 protein
13,14-dihydro-15-ketoprostaglandin D2 promotes the reaction [Flutamide results in increased expression of CXCL2 mRNA]

PMID:21094227 PMID:21735453

NCBI chr14:17,181,030...17,183,075
Ensembl chr14:17,181,062...17,183,075

G

GATA binding protein 3

multiple interactions

13,14-dihydro-15-ketoprostaglandin D2 promotes the reaction [Flutamide results in increased expression of GATA3 mRNA]

NCBI chr17:68,643,760...68,666,000
Ensembl chr17:68,643,873...68,665,391

G

interleukin 4

multiple interactions

13,14-dihydro-15-ketoprostaglandin D2 promotes the reaction [Flutamide results in increased expression of IL4 protein]

NCBI chr10:37,771,203...37,776,750
Ensembl chr10:37,771,203...37,776,750

G

prostaglandin D2 receptor

multiple interactions

13,14-dihydro-15-ketoprostaglandin D2 binds to and results in increased activity of PTGDR protein; 13,14-dihydro-15-ketoprostaglandin D2 inhibits the reaction [Prostaglandin D2 binds to PTGDR protein]

NCBI chr15:17,360,304...17,367,679
Ensembl chr15:17,360,304...17,367,679

G

prostaglandin D2 receptor 2

multiple interactions

13,14-dihydro-15-ketoprostaglandin D2 inhibits the reaction [Prostaglandin D2 binds to PTGDR2 protein]
13,14-dihydro-15-ketoprostaglandin D2 binds to and results in increased activity of PTGDR2 protein
13,14-dihydro-15-ketoprostaglandin D2 binds to and results in increased activity of PTGDR2 protein; ramatroban inhibits the reaction [13,14-dihydro-15-ketoprostaglandin D2 binds to and results in increased activity of PTGDR2 protein]

PMID:12721327 PMID:15528449 PMID:16256979

NCBI chr 1:207,585,088...207,590,275
Ensembl chr 1:207,587,917...207,589,213

13,14-dihydro-Delta(12)-prostaglandin J2

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

brain-derived neurotrophic factor

increases expression
multiple interactions

9-deoxy-9,10-didehydro-12,13-didehydro-13,14-dihydroprostaglandin D2 analog results in increased expression of BDNF mRNA
Dactinomycin inhibits the reaction [9-deoxy-9,10-didehydro-12,13-didehydro-13,14-dihydroprostaglandin D2 analog results in increased expression of BDNF mRNA]

NCBI chr 3:96,165,042...96,215,621
Ensembl chr 3:96,165,042...96,215,615

G

glial cell derived neurotrophic factor

multiple interactions
increases expression

Dactinomycin inhibits the reaction [9-deoxy-9,10-didehydro-12,13-didehydro-13,14-dihydroprostaglandin D2 analog results in increased expression of GDNF mRNA]; NFE2L2 protein affects the reaction [9-deoxy-9,10-didehydro-12,13-didehydro-13,14-dihydroprostaglandin D2 analog results in increased expression of GDNF mRNA]

NCBI chr 2:56,894,022...56,919,935
Ensembl chr 2:56,895,010...56,917,209

G

NFE2 like bZIP transcription factor 2

multiple interactions

NFE2L2 protein affects the reaction [9-deoxy-9,10-didehydro-12,13-didehydro-13,14-dihydroprostaglandin D2 analog results in increased expression of GDNF mRNA]

NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737

G

nerve growth factor

multiple interactions
increases expression

Dactinomycin inhibits the reaction [9-deoxy-9,10-didehydro-12,13-didehydro-13,14-dihydroprostaglandin D2 analog results in increased expression of NGF mRNA]

NCBI chr 2:189,901,058...189,954,452
Ensembl chr 2:189,901,058...189,954,452

15-deoxy-Delta(12,14)-prostaglandin J2

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily C member 1

multiple interactions
affects export
affects glutathionylation
increases transport

[ABCC1 protein results in increased transport of 15-deoxy-delta(12,14)-prostaglandin J2 metabolite] affects the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of GCLC protein]; [verlukast binds to and results in decreased activity of ABCC1 protein] inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of GCLC protein]; ABCC1 protein affects the reaction [15-deoxy-delta(12,14)-prostaglandin J2 promotes the reaction [NFE2L2 protein results in increased expression of GCLC protein]]; ABCC1 protein affects the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of GCLC protein]
ABCC1 protein affects the export of 15-deoxy-delta(12,14)-prostaglandin J2 analog
ABCC1 protein affects the glutathionylation of 15-deoxy-delta(12,14)-prostaglandin J2

PMID:14979731 PMID:21728338

NCBI chr10:528,961...655,179
Ensembl chr10:531,812...655,114

G

ATP binding cassette subfamily C member 3

affects export

ABCC3 protein affects the export of 15-deoxy-delta(12,14)-prostaglandin J2 analog

NCBI chr10:79,296,681...79,342,749
Ensembl chr10:79,296,693...79,342,595

G

acetyl-CoA acyltransferase 2

multiple interactions

[15-deoxy-delta(12,14)-prostaglandin J2 co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of ACAA2 mRNA

NCBI chr18:68,345,136...68,373,246
Ensembl chr18:68,345,012...68,373,249

G

adiponectin, C1Q and collagen domain containing

multiple interactions

[15-deoxy-delta(12,14)-prostaglandin J2 co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of ADIPOQ mRNA

NCBI chr11:77,721,912...77,735,644
Ensembl chr11:77,721,912...77,735,564

G

angiotensinogen

multiple interactions

15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [AGT protein results in decreased expression of PPARG protein]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [AGT protein results in increased expression of and results in increased secretion of SERPINE1 protein]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [AGT protein results in increased expression of SERPINE1 mRNA]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [AGT protein results in increased expression of TGFB1 protein]; 2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [AGT protein results in increased expression of and results in increased secretion of SERPINE1 protein]]; 2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [AGT protein results in increased expression of SERPINE1 mRNA]]; 2-chloro-5-nitrobenzanilide inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [AGT protein results in increased expression of and results in increased secretion of SERPINE1 protein]]; 2-chloro-5-nitrobenzanilide inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [AGT protein results in increased expression of SERPINE1 mRNA]]

NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977

G

aldo-keto reductase family 1, member C3

multiple interactions

[Medroxyprogesterone Acetate inhibits the reaction [[AKR1C3 protein results in increased metabolism of Prostaglandin D2] which results in increased abundance of Dinoprost]] which results in increased abundance of 15-deoxy-delta(12,14)-prostaglandin J2

NCBI chr17:66,110,970...66,127,867
Ensembl chr17:66,110,963...66,127,873

G

AKT serine/threonine kinase 1

multiple interactions

[15-deoxy-delta(12,14)-prostaglandin J2 co-treated with alitretinoin] results in decreased phosphorylation of AKT1 protein

NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921

G

bone gamma-carboxyglutamate protein

decreases expression

15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of BGLAP mRNA

NCBI chr 2:173,838,518...173,839,495
Ensembl chr 2:173,838,518...173,839,495

G

baculoviral IAP repeat-containing 2

decreases expression

15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of BIRC2 protein

NCBI chr 8:4,968,856...4,989,325
Ensembl chr 8:4,968,842...4,988,732

G

baculoviral IAP repeat-containing 3

decreases expression

15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of BIRC3 protein

NCBI chr 8:5,000,844...5,028,470
Ensembl chr 8:5,000,845...5,015,802

G

caspase 3

increases activity
multiple interactions
increases cleavage

15-deoxy-delta(12,14)-prostaglandin J2 results in increased activity of CASP3 protein
[delta(12)-prostaglandin J(2) co-treated with 9-deoxy-delta-9-prostaglandin D2 co-treated with 15-deoxy-delta(12,14)-prostaglandin J2] results in increased cleavage of CASP3 protein
15-deoxy-delta(12,14)-prostaglandin J2 results in increased cleavage of CASP3 protein
15-deoxy-delta(12,14)-prostaglandin J2 results in increased cleavage of and results in increased activity of CASP3 protein

PMID:11785780 PMID:15498850 PMID:16299251 PMID:23973622

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

caspase 8

multiple interactions

15-deoxy-delta(12,14)-prostaglandin J2 results in increased cleavage of and results in increased activity of CASP8 protein

NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542

G

caspase 9

multiple interactions

15-deoxy-delta(12,14)-prostaglandin J2 results in increased cleavage of and results in increased activity of CASP9 protein

NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626

G

catalase

multiple interactions

CAT protein inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased phosphorylation of STAT1 protein]]

NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478

G

C-C motif chemokine ligand 2

multiple interactions

15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [[Dexamethasone binds to NR3C1 protein] which results in decreased expression of CCL2 protein]

NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226

G

C-C motif chemokine ligand 5

multiple interactions

15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of CCL5 mRNA]

NCBI chr10:68,322,826...68,327,380
Ensembl chr10:68,322,829...68,327,377

G

cellular communication network factor 2

multiple interactions

15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [TGFB1 protein results in increased expression of and results in increased secretion of CCN2 protein]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [TGFB1 protein results in increased expression of CCN2 mRNA]; SMAD2 protein modified form affects the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [TGFB1 protein results in increased expression of CCN2]]

NCBI chr 1:20,802,199...20,805,315
Ensembl chr 1:20,802,199...20,805,734

G

cyclin A2

decreases expression

15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of CCNA2 protein

NCBI chr 2:119,427,239...119,433,645
Ensembl chr 2:119,426,089...119,433,577

G

cyclin B1

decreases expression

15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of CCNB1 protein

NCBI chr 2:31,912,190...31,921,163
Ensembl chr 2:31,912,193...31,921,172

G

cyclin D3

decreases expression

15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of CCND3 protein

NCBI chr 9:13,394,161...13,400,341
Ensembl chr 9:13,394,169...13,489,371

G

cyclin E1

decreases expression

15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of CCNE1 protein

NCBI chr 1:90,781,947...90,791,188
Ensembl chr 1:90,781,949...90,791,101

G

cyclin dependent kinase 2

decreases expression

15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of CDK2 protein

NCBI chr 7:1,129,878...1,137,431
Ensembl chr 7:1,129,811...1,137,403

G

cyclin-dependent kinase inhibitor 1A

increases expression
decreases expression

15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of CDKN1A
15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of CDKN1A protein

PMID:15254749 PMID:15729575

NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585

G

cyclin-dependent kinase inhibitor 1B

decreases expression

15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of CDKN1B protein

NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982

G

CCAAT/enhancer binding protein alpha

increases expression

15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of CEBPA mRNA

NCBI chr 1:87,759,631...87,762,303
Ensembl chr 1:87,759,433...87,762,412

G

CASP8 and FADD-like apoptosis regulator

decreases expression

15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of CFLAR protein

NCBI chr 9:60,185,338...60,236,173
Ensembl chr 9:60,185,452...60,237,034

G

component of inhibitor of nuclear factor kappa B kinase complex

multiple interactions

15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [Tetradecanoylphorbol Acetate results in increased activity of CHUK protein]
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [manganese chloride results in increased phosphorylation of CHUK protein]

PMID:15498850 PMID:22245093

NCBI chr 1:242,959,539...242,995,066
Ensembl chr 1:242,959,760...242,995,065

G

cell death-inducing DFFA-like effector c

multiple interactions

[15-deoxy-delta(12,14)-prostaglandin J2 co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of CIDEC mRNA

NCBI chr 4:146,569,288...146,582,173
Ensembl chr 4:146,569,289...146,582,173

G

collagen type I alpha 1 chain

decreases expression

15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of COL1A1 mRNA

NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624

G

colony stimulating factor 2

multiple interactions

15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein results in increased expression of CSF2 mRNA]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein results in increased expression of CSF2 protein]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [Lipopolysaccharides results in increased expression of CSF2 mRNA]; Dexamethasone promotes the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein results in increased expression of CSF2 mRNA]]

PMID:12604364 PMID:14998300

NCBI chr10:38,386,945...38,388,926
Ensembl chr10:38,386,945...38,389,199

G

early growth response 1

multiple interactions

15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [Oxygen deficiency results in increased expression of and results in increased activity of EGR1 protein]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [Oxygen deficiency results in increased expression of EGR1 mRNA]

NCBI chr18:26,462,967...26,466,766
Ensembl chr18:26,462,981...26,466,766

G

fatty acid binding protein 4

multiple interactions
increases expression

[15-deoxy-delta(12,14)-prostaglandin J2 co-treated with Tretinoin] results in increased expression of FABP4 mRNA
[15-deoxy-delta(12,14)-prostaglandin J2 co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of FABP4 mRNA
15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of FABP4 mRNA

PMID:9543393 PMID:12021203 PMID:16573735 PMID:34323617

NCBI chr 2:91,580,879...91,585,567
Ensembl chr 2:91,580,885...91,585,578

G

Fas cell surface death receptor

decreases expression

15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of FAS mRNA

NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591

G

Fos proto-oncogene, AP-1 transcription factor subunit

multiple interactions
increases expression

15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein results in increased activity of [FOS protein binds to JUN protein]]
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of FOS mRNA]; U 0126 inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of FOS mRNA]; wortmannin inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of FOS mRNA]

PMID:11457450 PMID:11687581

NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036

G

glutamate-cysteine ligase, catalytic subunit

multiple interactions
increases expression

15-deoxy-delta(12,14)-prostaglandin J2 promotes the reaction [NFE2L2 protein results in increased expression of GCLC protein]; [ABCC1 protein results in increased transport of 15-deoxy-delta(12,14)-prostaglandin J2 metabolite] affects the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of GCLC protein]; [verlukast binds to and results in decreased activity of ABCC1 protein] inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of GCLC protein]; ABCC1 protein affects the reaction [15-deoxy-delta(12,14)-prostaglandin J2 promotes the reaction [NFE2L2 protein results in increased expression of GCLC protein]]; ABCC1 protein affects the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of GCLC protein]; Acetylcysteine inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of GCLC protein]; NFE2L2 protein affects the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of GCLC protein]
15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of GCLC mRNA; 15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of GCLC protein

NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544

G

glial fibrillary acidic protein

increases expression
decreases expression
multiple interactions

15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of GFAP
15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of GFAP mRNA
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [ochratoxin A results in decreased expression of GFAP mRNA]

PMID:15254749 PMID:15994020

NCBI chr10:87,852,891...87,861,631
Ensembl chr10:87,852,890...87,861,589

G

glutathione S-transferase mu 1

multiple interactions

GSTM1 protein affects the metabolism of [15-deoxy-delta(12,14)-prostaglandin J2 co-treated with Glutathione]

NCBI chr 2:195,649,845...195,655,402
Ensembl chr 2:195,649,845...195,655,411

G

glutathione S-transferase pi 1

increases expression
multiple interactions

15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of GSTP1 mRNA; 15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of GSTP1 protein
Soybean Oil promotes the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of GSTP1 mRNA]; Soybean Oil promotes the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of GSTP1 protein]

NCBI chr 1:201,337,762...201,340,230
Ensembl chr 1:201,321,672...201,340,226

G

histone deacetylase 1

decreases expression

15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of HDAC1 mRNA

NCBI chr 5:141,853,992...141,881,057
Ensembl chr 5:141,853,989...141,881,111

G

histone deacetylase 2

decreases expression

15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of HDAC2 mRNA

NCBI chr20:40,548,244...40,571,609
Ensembl chr20:40,548,250...40,571,609

G

histone deacetylase 3

decreases expression

15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of HDAC3 mRNA

NCBI chr18:29,770,637...29,789,850
Ensembl chr18:29,770,636...29,793,856

G

hypoxia inducible factor 1 subunit alpha

affects stability
multiple interactions
increases expression

15-deoxy-delta(12,14)-prostaglandin J2 affects the stability of HIF1A protein
Acetylcysteine inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of HIF1A protein]; Buthionine Sulfoximine promotes the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of HIF1A protein]; Dithiothreitol inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of HIF1A protein]; Glutathione inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of HIF1A protein]

NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261

G

heme oxygenase 1

multiple interactions
increases expression

15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of and results in increased activity of HMOX1 protein; [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of and results in increased activity of HMOX1 protein] which results in increased abundance of Iron; [[15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of and results in increased activity of HMOX1 protein] which results in increased abundance of Iron] which results in increased abundance of Reactive Oxygen Species; [[15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of and results in increased activity of HMOX1 protein] which results in increased abundance of Iron] which results in increased expression of MMP1 mRNA; [[[15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of and results in increased activity of HMOX1 protein] which results in increased abundance of Iron] which results in increased abundance of Reactive Oxygen Species] which results in increased expression of MMP1 protein; Acetylcysteine inhibits the reaction [[[[15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of and results in increased activity of HMOX1 protein] which results in increased abundance of Iron] which results in increased abundance of Reactive Oxygen Species] which results in increased expression of MMP1 protein]; HMOX1 protein promotes the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of and results in increased activity of MMP1 protein]; HSF1 protein inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of HMOX1 mRNA]; NFE2L2 protein promotes the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of HMOX1 mRNA]; zinc protoporphyrin inhibits the reaction [[15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of and results in increased activity of HMOX1 protein] which results in increased abundance of Iron]
ochratoxin A inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of HMOX1 mRNA]
15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of HMOX1 mRNA; 15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of HMOX1 protein

PMID:11078701 PMID:15618017 PMID:15994020 PMID:19136476

NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079

G

heat shock transcription factor 1

multiple interactions
increases activity

HSF1 protein inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of HMOX1 mRNA]
15-deoxy-delta(12,14)-prostaglandin J2 results in increased activity of HSF1 protein

PMID:15618017 PMID:34170685

NCBI chr 7:108,196,040...108,223,011
Ensembl chr 7:108,196,056...108,223,011

G

heat shock protein family B (small) member 1

decreases expression

15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of HSPB1 protein

NCBI chr12:20,794,014...20,795,675
Ensembl chr12:20,794,028...20,795,743

G

interferon gamma

multiple interactions
decreases expression
decreases secretion

15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [[IFNG protein results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased activity of and results in increased localization of [STAT1 protein binds to STAT1 protein]]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased expression of IRF1 mRNA]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased expression of NOS2 mRNA]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased phosphorylation of and results in increased activity of JAK2 protein]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased phosphorylation of STAT1 protein]; 2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in decreased secretion of IFNG protein]; Acetylcysteine inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased phosphorylation of and results in increased activity of JAK2 protein]]; Acetylcysteine inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased phosphorylation of STAT1 protein]]; CAT protein inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased phosphorylation of STAT1 protein]]; Glutathione inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased phosphorylation of and results in increased activity of JAK2 protein]]; Glutathione inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased phosphorylation of STAT1 protein]]; Hydrogen Peroxide promotes the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased phosphorylation of STAT1 protein]]; peroxyvanadate inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased abundance of Nitric Oxide]]; peroxyvanadate inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased phosphorylation of STAT1 protein]]; T 0070907 inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in decreased secretion of IFNG protein]
15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of IFNG protein

PMID:12847270 PMID:16844232 PMID:19888466

NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375

G

interleukin 1 alpha

multiple interactions

15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein results in increased expression of IL1A mRNA]

NCBI chr 3:116,526,601...116,537,055
Ensembl chr 3:116,526,604...116,536,822

G

interleukin 1 beta

multiple interactions
decreases expression
decreases activity

15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein affects the localization of RELA protein]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein results in decreased abundance of Prostaglandins]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein results in increased abundance of Nitric Oxide]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein results in increased activity of [FOS protein binds to JUN protein]]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein results in increased activity of [RELA protein binds to NFKB1 protein]]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein results in increased expression of CSF2 mRNA]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein results in increased expression of CSF2 protein]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein results in increased expression of CXCL8 mRNA]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein results in increased expression of IL1A mRNA]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein results in increased expression of NOS2 mRNA]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein results in increased expression of PTGS2 mRNA]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]; 15-deoxy-delta(12,14)-prostaglandin J2 promotes the reaction [IL1B protein affects the localization of JUN protein]; Dexamethasone promotes the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein results in increased expression of CSF2 mRNA]]
15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of IL1B protein
[15-deoxy-delta(12,14)-prostaglandin J2 co-treated with IL1B protein] results in decreased secretion of IL1B protein
15-deoxy-delta(12,14)-prostaglandin J2 results in decreased activity of IL1B protein

PMID:11457450 PMID:12604364 PMID:14998300 PMID:15751073 PMID:16461118

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

interleukin 1 receptor antagonist

decreases expression

15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of IL1RN mRNA

NCBI chr 3:7,111,567...7,127,451
Ensembl chr 3:7,111,550...7,127,445

G

interleukin 4

multiple interactions

15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased degradation of NFKBIA protein]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of CCL5 mRNA]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of CXCL8 mRNA]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP mRNA]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP protein]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [amorolfine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of 15-deoxy-delta(12,14)-prostaglandin J2]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [butenafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of 15-deoxy-delta(12,14)-prostaglandin J2]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [Itraconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of 15-deoxy-delta(12,14)-prostaglandin J2]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [Ketoconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of 15-deoxy-delta(12,14)-prostaglandin J2]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [luliconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of 15-deoxy-delta(12,14)-prostaglandin J2]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [Terbinafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of 15-deoxy-delta(12,14)-prostaglandin J2]]; [Poly I-C co-treated with IL4 protein] results in decreased secretion of 15-deoxy-delta(12,14)-prostaglandin J2; amorolfine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of 15-deoxy-delta(12,14)-prostaglandin J2]; butenafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of 15-deoxy-delta(12,14)-prostaglandin J2]; Itraconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of 15-deoxy-delta(12,14)-prostaglandin J2]; Ketoconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of 15-deoxy-delta(12,14)-prostaglandin J2]; luliconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of 15-deoxy-delta(12,14)-prostaglandin J2]; Terbinafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of 15-deoxy-delta(12,14)-prostaglandin J2]

NCBI chr10:37,771,203...37,776,750
Ensembl chr10:37,771,203...37,776,750

G

interleukin 6

multiple interactions

15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL6 protein results in increased phosphorylation of STAT1 protein]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL6 protein results in increased phosphorylation of STAT3 protein]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]

PMID:12604364 PMID:12847270

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

insulin 1

multiple interactions

[15-deoxy-delta(12,14)-prostaglandin J2 co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of ACAA2 mRNA; [15-deoxy-delta(12,14)-prostaglandin J2 co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of ADIPOQ mRNA; [15-deoxy-delta(12,14)-prostaglandin J2 co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of CIDEC mRNA; [15-deoxy-delta(12,14)-prostaglandin J2 co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of FABP4 mRNA; [15-deoxy-delta(12,14)-prostaglandin J2 co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of PLIN1 mRNA; [15-deoxy-delta(12,14)-prostaglandin J2 co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of PPARA mRNA

NCBI chr 1:251,244,973...251,245,540
Ensembl chr 1:251,244,973...251,245,536

G

insulin 2

multiple interactions

15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [Fatty Acids, Nonesterified inhibits the reaction [INS protein results in increased secretion of Glucose]]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [Fatty Acids, Nonesterified results in decreased expression of INS mRNA]

NCBI chr 1:197,843,277...197,992,522
Ensembl chr 1:197,843,281...197,864,775

G

interferon regulatory factor 1

multiple interactions

15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased expression of IRF1 mRNA]

NCBI chr10:37,917,155...37,924,166
Ensembl chr10:37,916,670...37,924,166

G

Janus kinase 2

multiple interactions

15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased phosphorylation of and results in increased activity of JAK2 protein]; Acetylcysteine inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased phosphorylation of and results in increased activity of JAK2 protein]]; Glutathione inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased phosphorylation of and results in increased activity of JAK2 protein]]

NCBI chr 1:226,995,334...227,054,381
Ensembl chr 1:226,995,334...227,054,189

G

Jun proto-oncogene, AP-1 transcription factor subunit

multiple interactions

15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein results in increased activity of [FOS protein binds to JUN protein]]; 15-deoxy-delta(12,14)-prostaglandin J2 promotes the reaction [IL1B protein affects the localization of JUN protein]

NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656

G

KLF transcription factor 6

multiple interactions

[15-deoxy-delta(12,14)-prostaglandin J2 co-treated with alitretinoin] results in decreased phosphorylation of KLF6 protein; RPS6KB1 protein inhibits the reaction [[15-deoxy-delta(12,14)-prostaglandin J2 co-treated with alitretinoin] results in decreased phosphorylation of KLF6 protein]

NCBI chr17:64,539,456...64,548,451
Ensembl chr17:64,531,463...64,588,570

G

leptin

multiple interactions
increases secretion

[Dexamethasone co-treated with 15-deoxy-delta(12,14)-prostaglandin J2] results in decreased secretion of LEP protein
15-deoxy-delta(12,14)-prostaglandin J2 results in increased secretion of LEP protein

NCBI chr 4:57,661,127...57,675,262
Ensembl chr 4:57,661,131...57,675,262

G

LIF, interleukin 6 family cytokine

multiple interactions

15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [LIF protein results in increased expression of STAT3 protein]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [LIF protein results in increased phosphorylation of STAT3 protein]; 2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [LIF protein results in increased expression of STAT3 protein]]; 2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [LIF protein results in increased phosphorylation of STAT3 protein]]; T 0070907 inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [LIF protein results in increased expression of STAT3 protein]]; T 0070907 inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [LIF protein results in increased phosphorylation of STAT3 protein]]

NCBI chr14:79,131,049...79,140,486
Ensembl chr14:79,134,574...79,140,482

G

lipoprotein lipase

increases expression

15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of LPL mRNA

NCBI chr16:20,830,055...20,853,855
Ensembl chr16:20,829,465...20,855,249

G

mitogen activated protein kinase 1

decreases phosphorylation
multiple interactions
increases phosphorylation

15-deoxy-delta(12,14)-prostaglandin J2 results in decreased phosphorylation of MAPK1 protein
15-deoxy-delta(12,14)-prostaglandin J2 results in increased phosphorylation of and results in increased activity of MAPK1 protein; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased phosphorylation of and results in increased activity of MAPK1 protein]; U 0126 inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased phosphorylation of and results in increased activity of MAPK1 protein]
15-deoxy-delta(12,14)-prostaglandin J2 results in increased phosphorylation of MAPK1 protein
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased phosphorylation of MAPK1 protein]; [15-deoxy-delta(12,14)-prostaglandin J2 co-treated with alitretinoin] results in decreased phosphorylation of MAPK1 protein; Glutathione inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased phosphorylation of MAPK1 protein]; manganese(III)-tetrakis(4-benzoic acid)porphyrin inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased phosphorylation of MAPK1 protein]

PMID:11687581 PMID:12083801 PMID:16611854 PMID:19888466

NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616

G

mitogen activated protein kinase 3

decreases phosphorylation
multiple interactions
increases phosphorylation

15-deoxy-delta(12,14)-prostaglandin J2 results in decreased phosphorylation of MAPK3 protein
15-deoxy-delta(12,14)-prostaglandin J2 results in increased phosphorylation of and results in increased activity of MAPK3 protein; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased phosphorylation of and results in increased activity of MAPK3 protein]; U 0126 inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased phosphorylation of and results in increased activity of MAPK3 protein]
15-deoxy-delta(12,14)-prostaglandin J2 results in increased phosphorylation of MAPK3 protein
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased phosphorylation of MAPK3 protein]; [15-deoxy-delta(12,14)-prostaglandin J2 co-treated with alitretinoin] results in decreased phosphorylation of MAPK3 protein; Glutathione inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased phosphorylation of MAPK3 protein]; manganese(III)-tetrakis(4-benzoic acid)porphyrin inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased phosphorylation of MAPK3 protein]

PMID:11687581 PMID:12083801 PMID:16611854 PMID:19888466

NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863

G

mediator complex subunit 1

multiple interactions

MED1 protein promotes the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased activity of PPARG protein]

NCBI chr10:83,145,538...83,189,260
Ensembl chr10:83,145,568...83,189,299

G

matrix metallopeptidase 1

multiple interactions
increases expression

15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of and results in increased activity of MMP1 protein; [[15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of and results in increased activity of HMOX1 protein] which results in increased abundance of Iron] which results in increased expression of MMP1 mRNA; [[[15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of and results in increased activity of HMOX1 protein] which results in increased abundance of Iron] which results in increased abundance of Reactive Oxygen Species] which results in increased expression of MMP1 protein; Acetylcysteine inhibits the reaction [[[[15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of and results in increased activity of HMOX1 protein] which results in increased abundance of Iron] which results in increased abundance of Reactive Oxygen Species] which results in increased expression of MMP1 protein]; Cycloheximide inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of MMP1 protein]; Dactinomycin inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of MMP1 protein]; Deferoxamine inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of MMP1 mRNA]; Deferoxamine inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of MMP1 protein]; HMOX1 protein promotes the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of and results in increased activity of MMP1 protein]; NFE2L2 protein promotes the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of MMP1 mRNA]

NCBI chr 8:4,658,588...4,679,099
Ensembl chr 8:4,658,588...4,679,097

G

matrix metallopeptidase 9

multiple interactions
decreases expression

15-deoxy-delta(12,14)-prostaglandin J2 results in decreased activity of and results in decreased expression of MMP9 protein; 2-chloro-5-nitrobenzanilide inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in decreased activity of and results in decreased expression of MMP9 protein]; 2-chloro-5-nitrobenzanilide inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of MMP9 mRNA]

NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120

G

mechanistic target of rapamycin kinase

multiple interactions

[15-deoxy-delta(12,14)-prostaglandin J2 co-treated with alitretinoin] results in decreased phosphorylation of MTOR protein

NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311

G

nestin

increases expression

15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of NES protein

NCBI chr 2:173,437,867...173,447,777
Ensembl chr 2:173,438,734...173,447,777

G

NFE2 like bZIP transcription factor 2

multiple interactions

15-deoxy-delta(12,14)-prostaglandin J2 affects the localization of and results in increased activity of NFE2L2 protein; 15-deoxy-delta(12,14)-prostaglandin J2 promotes the reaction [NFE2L2 protein results in increased expression of GCLC protein]; ABCC1 protein affects the reaction [15-deoxy-delta(12,14)-prostaglandin J2 promotes the reaction [NFE2L2 protein results in increased expression of GCLC protein]]; Acetylcysteine inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased activity of NFE2L2 protein]; NFE2L2 protein affects the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of GCLC protein]; NFE2L2 protein promotes the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of HMOX1 mRNA]; NFE2L2 protein promotes the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of MMP1 mRNA]
15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of and affects the localization of NFE2L2 protein; manganese chloride inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of NFE2L2 protein]

PMID:19136476 PMID:21728338 PMID:22245093

NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737

G

nuclear factor kappa B subunit 1

multiple interactions
decreases localization

15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein results in increased activity of [RELA protein binds to NFKB1 protein]]
15-deoxy-delta(12,14)-prostaglandin J2 results in decreased localization of NFKB1 protein

PMID:11457450 PMID:16299251

NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404

G

NFKB inhibitor alpha

multiple interactions
decreases phosphorylation

15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased degradation of NFKBIA protein]
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [manganese chloride results in increased degradation of NFKBIA protein]
15-deoxy-delta(12,14)-prostaglandin J2 results in decreased phosphorylation of NFKBIA protein

PMID:15498850 PMID:22245093 PMID:23688403

NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941

G

nitric oxide synthase 2

multiple interactions
decreases activity
decreases expression

15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein results in increased expression of NOS2 mRNA]
15-deoxy-delta(12,14)-prostaglandin J2 results in decreased activity of NOS2 protein
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [ochratoxin A results in increased expression of NOS2 mRNA]; 15-deoxy-delta(12,14)-prostaglandin J2 results in decreased activity of and results in decreased expression of NOS2 protein
15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of NOS2 mRNA
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [[IFNG protein results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [Bleomycin results in increased expression of NOS2 protein]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased expression of NOS2 mRNA]; 15-deoxy-delta(12,14)-prostaglandin J2 results in decreased activity of and results in decreased expression of NOS2 protein; 2-chloro-5-nitrobenzanilide inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in decreased activity of and results in decreased expression of NOS2 protein]; 2-chloro-5-nitrobenzanilide inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of NOS2 mRNA]

PMID:11457450 PMID:11890746 PMID:12847270 PMID:15684285 PMID:15994020 More...

NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210

G

nitric oxide synthase 3

decreases activity

15-deoxy-delta(12,14)-prostaglandin J2 results in decreased activity of NOS3 protein

NCBI chr 4:10,793,834...10,814,170
Ensembl chr 4:10,793,834...10,814,166

G

nuclear receptor subfamily 3, group C, member 1

affects activity
multiple interactions

15-deoxy-delta(12,14)-prostaglandin J2 affects the activity of NR3C1 protein
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [[Dexamethasone binds to NR3C1 protein] which results in decreased expression of CCL2 protein]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [Dexamethasone binds to NR3C1 protein]

NCBI chr18:31,271,681...31,393,320
Ensembl chr18:31,271,681...31,393,375

G

Parkinsonism associated deglycase

multiple interactions

15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [manganese chloride results in decreased expression of PARK7 mRNA]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [manganese chloride results in decreased expression of PARK7 protein]

NCBI chr 5:161,353,718...161,376,993
Ensembl chr 5:161,353,719...161,376,970

G

poly (ADP-ribose) polymerase 1

increases cleavage
multiple interactions

15-deoxy-delta(12,14)-prostaglandin J2 results in increased cleavage of PARP1 protein
[delta(12)-prostaglandin J(2) co-treated with 9-deoxy-delta-9-prostaglandin D2 co-treated with 15-deoxy-delta(12,14)-prostaglandin J2] results in increased cleavage of PARP1 protein

PMID:15498850 PMID:23973622

NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404

G

phosphoenolpyruvate carboxykinase 1

increases expression

15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of PCK1 mRNA

NCBI chr 3:161,930,256...161,936,205
Ensembl chr 3:161,930,256...161,936,191

G

perilipin 1

multiple interactions

[15-deoxy-delta(12,14)-prostaglandin J2 co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of PLIN1 mRNA

NCBI chr 1:133,664,294...133,676,854
Ensembl chr 1:133,664,892...133,676,828

G

peroxisome proliferator activated receptor alpha

multiple interactions

15-deoxy-delta(12,14)-prostaglandin J2 binds to and results in increased activity of PPARA protein
[15-deoxy-delta(12,14)-prostaglandin J2 co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of PPARA mRNA

PMID:9013583 PMID:34323617

NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346

G

peroxisome proliferator-activated receptor delta

increases expression

15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of PPARD protein

NCBI chr20:6,298,785...6,363,970
Ensembl chr20:6,298,785...6,363,968

G

peroxisome proliferator-activated receptor gamma

affects expression
decreases response to substance
increases expression
increases activity
multiple interactions
decreases expression

15-deoxy-delta(12,14)-prostaglandin J2 affects the expression of PPARG
PPARG protein mutant form results in decreased susceptibility to 15-deoxy-delta(12,14)-prostaglandin J2
15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of PPARG mRNA; 15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of PPARG protein
15-deoxy-delta(12,14)-prostaglandin J2 results in increased activity of PPARG protein
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [AGT protein results in decreased expression of PPARG protein]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [ochratoxin A results in increased expression of PPARG mRNA]
15-deoxy-delta(12,14)-prostaglandin J2 binds to and results in increased activity of PPARG protein; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [PPARG protein affects the reaction [Lipopolysaccharides results in increased abundance of Nitric Oxide]]; MED1 protein promotes the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased activity of PPARG protein]
15-deoxy-delta(12,14)-prostaglandin J2 affects the localization of and results in increased expression of PPARG protein; 15-deoxy-delta(12,14)-prostaglandin J2 binds to and results in decreased activity of PPARG protein; 15-deoxy-delta(12,14)-prostaglandin J2 binds to and results in increased activity of PPARG protein; 15-deoxy-delta(12,14)-prostaglandin J2 binds to and results in increased localization of and results in increased activity of PPARG protein; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [deoxynivalenol results in increased expression of PPARG protein]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [Fatty Acids, Nonesterified results in decreased expression of PPARG mRNA]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [Lipopolysaccharides results in decreased expression of PPARG mRNA]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased activity of PPARG protein]; MG 262 promotes the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased activity of PPARG protein]; PPARG protein affects the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of TBXA2R mRNA alternative form]
15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of PPARG protein

PMID:9013583 PMID:10662598 PMID:11030710 PMID:12065695 PMID:12604364 More...

NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468

G

phosphatase and tensin homolog

multiple interactions

[15-deoxy-delta(12,14)-prostaglandin J2 co-treated with alitretinoin] results in increased expression of PTEN protein

NCBI chr 1:230,630,443...230,697,070
Ensembl chr 1:230,630,338...230,696,838

G

prostaglandin D2 receptor

multiple interactions

15-deoxy-delta(12,14)-prostaglandin J2 binds to and results in increased activity of PTGDR protein; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [Prostaglandin D2 binds to PTGDR protein]

NCBI chr15:17,360,304...17,367,679
Ensembl chr15:17,360,304...17,367,679

G

prostaglandin D2 receptor 2

multiple interactions

15-deoxy-delta(12,14)-prostaglandin J2 binds to and results in increased activity of PTGDR2 protein; ramatroban inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 binds to and results in increased activity of PTGDR2 protein]
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [Prostaglandin D2 binds to PTGDR2 protein]

PMID:12721327 PMID:16256979

NCBI chr 1:207,585,088...207,590,275
Ensembl chr 1:207,587,917...207,589,213

G

prostaglandin-endoperoxide synthase 1

multiple interactions

PTGS1 protein promotes the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased abundance of 15-deoxy-delta(12,14)-prostaglandin J2]

NCBI chr 3:19,584,015...19,605,589
Ensembl chr 3:19,584,015...19,605,586

G

prostaglandin-endoperoxide synthase 2

multiple interactions
decreases expression
increases expression

15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein results in increased expression of PTGS2 mRNA]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 mRNA]
15-deoxy-delta(12,14)-prostaglandin J2 results in decreased activity of and results in decreased expression of PTGS2 protein; 2-chloro-5-nitrobenzanilide inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in decreased activity of and results in decreased expression of PTGS2 protein]; 2-chloro-5-nitrobenzanilide inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of PTGS2 mRNA]
15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of PTGS2

PMID:11457450 PMID:12604364 PMID:15254749 PMID:19997048

NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188

G

protein tyrosine phosphatase, non-receptor type 11

increases phosphorylation

15-deoxy-delta(12,14)-prostaglandin J2 results in increased phosphorylation of PTPN11 protein

NCBI chr12:35,365,436...35,424,925
Ensembl chr12:35,383,144...35,424,925

G

Raf-1 proto-oncogene, serine/threonine kinase

multiple interactions

15-deoxy-delta(12,14)-prostaglandin J2 results in increased activity of and results in decreased phosphorylation of RAF1 protein

NCBI chr 4:148,679,534...148,740,265
Ensembl chr 4:148,679,530...148,740,317

G

retinoic acid receptor, beta

multiple interactions
increases expression

15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [ciglitazone promotes the reaction [SR 11237 results in increased expression of RARB protein]]
15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of RARB

PMID:12839938 PMID:15254749

NCBI chr15:8,700,533...9,051,288
Ensembl chr15:8,406,492...9,051,288

G

RB transcriptional corepressor 1

multiple interactions

15-deoxy-delta(12,14)-prostaglandin J2 results in decreased phosphorylation of and results in decreased expression of RB1 protein

NCBI chr15:48,371,295...48,502,473
Ensembl chr15:48,371,296...48,502,302

G

RELA proto-oncogene, NF-kB subunit

multiple interactions
decreases activity

15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein affects the localization of RELA protein]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein results in increased activity of [RELA protein binds to NFKB1 protein]]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [Lipopolysaccharides results in increased activity of RELA protein]
15-deoxy-delta(12,14)-prostaglandin J2 results in decreased activity of RELA protein
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [manganese chloride affects the localization of RELA protein]

PMID:11457450 PMID:15498850 PMID:20174873 PMID:22245093

NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484

G

RNA sensor RIG-1

multiple interactions

15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [Lipopolysaccharides results in increased expression of RIGI mRNA]

NCBI chr 5:55,321,351...55,369,947
Ensembl chr 5:55,321,235...55,370,819

G

ribosomal protein S6 kinase A1

multiple interactions

[15-deoxy-delta(12,14)-prostaglandin J2 co-treated with alitretinoin] results in decreased phosphorylation of RPS6KA1 protein

NCBI chr 5:146,079,018...146,118,272
Ensembl chr 5:146,079,021...146,118,272

G

ribosomal protein S6 kinase B1

multiple interactions

[15-deoxy-delta(12,14)-prostaglandin J2 co-treated with alitretinoin] results in decreased phosphorylation of and results in decreased activity of RPS6KB1 protein; RPS6KB1 protein inhibits the reaction [[15-deoxy-delta(12,14)-prostaglandin J2 co-treated with alitretinoin] results in decreased expression of TGFB1 mRNA]; RPS6KB1 protein inhibits the reaction [[15-deoxy-delta(12,14)-prostaglandin J2 co-treated with alitretinoin] results in decreased phosphorylation of KLF6 protein]

NCBI chr10:71,323,777...71,367,908
Ensembl chr10:71,323,777...71,367,908

G

RUNX family transcription factor 2

decreases expression

15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of RUNX2 mRNA

NCBI chr 9:16,167,504...16,492,826
Ensembl chr 9:16,167,482...16,492,167

G

retinoid X receptor alpha

increases expression

15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of RXRA

NCBI chr 3:10,989,832...11,076,366
Ensembl chr 3:10,989,832...11,073,712

G

serpin family E member 1

multiple interactions

15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [AGT protein results in increased expression of and results in increased secretion of SERPINE1 protein]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [AGT protein results in increased expression of SERPINE1 mRNA]; 2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [AGT protein results in increased expression of and results in increased secretion of SERPINE1 protein]]; 2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [AGT protein results in increased expression of SERPINE1 mRNA]]; 2-chloro-5-nitrobenzanilide inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [AGT protein results in increased expression of and results in increased secretion of SERPINE1 protein]]; 2-chloro-5-nitrobenzanilide inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [AGT protein results in increased expression of SERPINE1 mRNA]]

NCBI chr12:19,601,272...19,611,657
Ensembl chr12:19,601,272...19,611,657

G

SMAD family member 2

multiple interactions

15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [TGFB1 protein results in increased phosphorylation of SMAD2 protein]; SMAD2 protein modified form affects the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [TGFB1 protein results in increased expression of CCN2]]

NCBI chr18:69,849,884...69,918,926
Ensembl chr18:69,850,377...69,912,323

G

suppressor of cytokine signaling 1

increases expression

15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of SOCS1 mRNA

NCBI chr10:4,882,651...4,884,342
Ensembl chr10:4,882,560...4,884,383

G

suppressor of cytokine signaling 3

increases expression

15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of SOCS3 mRNA

NCBI chr10:103,193,909...103,197,322
Ensembl chr10:103,193,537...103,197,787

G

secreted phosphoprotein 1

decreases expression

15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of SPP1 mRNA

NCBI chr14:5,308,885...5,315,120
Ensembl chr14:5,308,885...5,315,162

G

signal transducer and activator of transcription 1

multiple interactions

15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL6 protein results in increased phosphorylation of STAT1 protein]
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of STAT1 protein]
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased activity of and results in increased localization of [STAT1 protein binds to STAT1 protein]]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased phosphorylation of STAT1 protein]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [peroxyvanadate results in increased phosphorylation of STAT1 protein]; Acetylcysteine inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased phosphorylation of STAT1 protein]]; CAT protein inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased phosphorylation of STAT1 protein]]; Glutathione inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased phosphorylation of STAT1 protein]]; Hydrogen Peroxide promotes the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased phosphorylation of STAT1 protein]]; peroxyvanadate inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased phosphorylation of STAT1 protein]]

PMID:12584205 PMID:12847270

NCBI chr 9:49,419,561...49,459,969
Ensembl chr 9:49,419,340...49,588,540

G

signal transducer and activator of transcription 3

multiple interactions

15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [LIF protein results in increased expression of STAT3 protein]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [LIF protein results in increased phosphorylation of STAT3 protein]; 2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [LIF protein results in increased expression of STAT3 protein]]; 2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [LIF protein results in increased phosphorylation of STAT3 protein]]; T 0070907 inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [LIF protein results in increased expression of STAT3 protein]]; T 0070907 inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [LIF protein results in increased phosphorylation of STAT3 protein]]
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of STAT3 protein]
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL6 protein results in increased phosphorylation of STAT3 protein]

PMID:12584205 PMID:12847270 PMID:19922793

NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057

G

thromboxane A2 receptor

multiple interactions
decreases expression

PPARG protein affects the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of TBXA2R mRNA alternative form]

NCBI chr 7:8,383,347...8,390,753
Ensembl chr 7:8,383,378...8,388,176

G

thyroglobulin

multiple interactions
increases expression

15-deoxy-delta(12,14)-prostaglandin J2 promotes the reaction [TSHB protein results in increased expression of TG protein]
15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of TG protein

NCBI chr 7:98,418,293...98,603,210
Ensembl chr 7:98,418,293...98,603,210

G

transforming growth factor, beta 1

multiple interactions
decreases expression
decreases response to substance

15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [TGFB1 protein results in increased expression of and results in increased secretion of CCN2 protein]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [TGFB1 protein results in increased expression of CCN2 mRNA]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [TGFB1 protein results in increased phosphorylation of SMAD2 protein]; SMAD2 protein modified form affects the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [TGFB1 protein results in increased expression of CCN2]]
15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of TGFB1 mRNA
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [AGT protein results in increased expression of TGFB1 protein]
15-deoxy-delta(12,14)-prostaglandin J2 promotes the reaction [alitretinoin results in decreased expression of TGFB1 mRNA]; 2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [[alitretinoin co-treated with 15-deoxy-delta(12,14)-prostaglandin J2] results in decreased expression of TGFB1 mRNA]; 2-chloro-5-nitrobenzanilide inhibits the reaction [[alitretinoin co-treated with 15-deoxy-delta(12,14)-prostaglandin J2] results in decreased expression of TGFB1 mRNA]; RPS6KB1 protein inhibits the reaction [[15-deoxy-delta(12,14)-prostaglandin J2 co-treated with alitretinoin] results in decreased expression of TGFB1 mRNA]
15-deoxy-delta(12,14)-prostaglandin J2 results in decreased susceptibility to TGFB1 protein

PMID:16611854 PMID:18278065 PMID:19429239

NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847

G

tyrosine hydroxylase

increases expression

15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of TH protein

NCBI chr 1:198,071,500...198,078,832
Ensembl chr 1:198,071,503...198,109,767

G

toll-like receptor 2

multiple interactions
decreases expression

15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [Lipopolysaccharides results in increased expression of TLR2 mRNA]
15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of TLR2 mRNA

NCBI chr 2:169,200,620...169,206,819
Ensembl chr 2:169,197,419...169,206,630

G

tumor necrosis factor

decreases expression
multiple interactions

15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of TNF protein
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]

PMID:12604364 PMID:19888466

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

G

thyroid stimulating hormone subunit beta

multiple interactions

15-deoxy-delta(12,14)-prostaglandin J2 promotes the reaction [TSHB protein results in increased expression of TG protein]

NCBI chr 2:190,224,676...190,229,559
Ensembl chr 2:190,224,676...190,229,559

G

thymic stromal lymphopoietin

multiple interactions

15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP mRNA]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP protein]

NCBI chr18:24,447,409...24,454,244
Ensembl chr18:24,449,844...24,453,548

G

vimentin

decreases expression

15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of VIM

NCBI chr17:76,668,701...76,677,186
Ensembl chr17:76,668,647...76,677,187

G

Wnt family member 10B

decreases expression

15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of WNT10B mRNA

NCBI chr 7:129,922,088...129,927,892
Ensembl chr 7:129,922,088...129,927,892

G

X-linked inhibitor of apoptosis

decreases expression

15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of XIAP protein

PMID:15498850 PMID:16299251

NCBI chr X:120,890,537...120,938,413
Ensembl chr X:120,897,907...120,934,700

16,16-dimethylprostaglandin E2

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

AKT serine/threonine kinase 1

increases phosphorylation
multiple interactions

16,16-Dimethylprostaglandin E2 results in increased phosphorylation of AKT1 protein
EGFR affects the reaction [16,16-Dimethylprostaglandin E2 results in increased phosphorylation of AKT1 protein]

NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921

G

BCL2 associated X, apoptosis regulator

increases response to substance
affects localization

BAX results in increased susceptibility to 16,16-Dimethylprostaglandin E2
16,16-Dimethylprostaglandin E2 affects the localization of BAX protein

NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368

G

epidermal growth factor receptor

multiple interactions

EGFR affects the reaction [16,16-Dimethylprostaglandin E2 results in increased phosphorylation of AKT1 protein]

NCBI chr14:91,176,979...91,349,722
Ensembl chr14:91,177,067...91,344,382

G

15-hydroxyprostaglandin dehydrogenase

increases activity

16,16-Dimethylprostaglandin E2 results in increased activity of HPGD protein

NCBI chr16:33,986,265...34,024,228
Ensembl chr16:33,986,266...34,024,228

G

myeloperoxidase

multiple interactions

16,16-Dimethylprostaglandin E2 inhibits the reaction [Indomethacin results in increased activity of MPO protein]

PMID:11686837 PMID:11855677 PMID:11991626 PMID:18306037

NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819

G

nitric oxide synthase 2

multiple interactions

16,16-Dimethylprostaglandin E2 inhibits the reaction [Indomethacin results in increased activity of NOS2 protein]; 16,16-Dimethylprostaglandin E2 inhibits the reaction [Indomethacin results in increased expression of NOS2 mRNA]

PMID:11686837 PMID:11855677 PMID:11991626 PMID:15610444 PMID:18306037

NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210

G

prostaglandin-endoperoxide synthase 2

multiple interactions
increases expression

Flurbiprofen inhibits the reaction [16,16-Dimethylprostaglandin E2 results in increased expression of PTGS2 mRNA]
16,16-Dimethylprostaglandin E2 inhibits the reaction [SC 560 results in increased expression of PTGS2 mRNA]

PMID:9099957 PMID:15610444

NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188

G

tumor necrosis factor

multiple interactions

16,16-Dimethylprostaglandin E2 inhibits the reaction [Lipopolysaccharides results in increased expression of TNF]

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

2-cyclopenten-1-one

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

caspase 3

multiple interactions

cyclopentenone results in increased cleavage of and results in increased activity of CASP3 protein

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

cyclin-dependent kinase inhibitor 1B

increases expression

cyclopentenone results in increased expression of CDKN1B

NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982

G

RB transcriptional corepressor 1

decreases phosphorylation

cyclopentenone results in decreased phosphorylation of RB1 protein

NCBI chr15:48,371,295...48,502,473
Ensembl chr15:48,371,296...48,502,302

2-methoxyestrone

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

hydroxysteroid (17-beta) dehydrogenase 2

multiple interactions

[HSD17B2 protein results in increased metabolism of and results in decreased activity of 2-methoxyestradiol] which results in increased chemical synthesis of 2-methoxyestrone

NCBI chr19:45,753,576...45,825,203
Ensembl chr19:45,753,574...45,825,202

28-deoxonimbolide

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

caspase 3

increases activity

28-deoxonimbolide results in increased activity of CASP3 protein

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

caspase 8

increases activity

28-deoxonimbolide results in increased activity of CASP8 protein

NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542

G

caspase 9

increases activity

28-deoxonimbolide results in increased activity of CASP9 protein

NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626

AH23848

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

AKT serine/threonine kinase 1

multiple interactions

[6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] inhibits the reaction [GSK3B protein binds to AKT1 protein]; [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] results in decreased phosphorylation of AKT1 protein

NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921

G

arrestin, beta 1

multiple interactions

[6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] inhibits the reaction [[ARRB1 protein modified form binds to SRC protein] which binds to IL1R1 protein]; [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] inhibits the reaction [[ARRB1 protein modified form binds to SRC protein] which binds to TNFRSF1A protein]; [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] inhibits the reaction [ARRB1 protein modified form binds to SRC protein]; [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] results in decreased phosphorylation of ARRB1 protein

NCBI chr 1:153,837,964...153,912,111
Ensembl chr 1:153,838,078...153,904,061

G

axin 1

multiple interactions

[6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] promotes the reaction [AXIN1 protein binds to CTNNB1 protein]

NCBI chr10:15,163,477...15,215,615
Ensembl chr10:15,163,684...15,215,615

G

BCL2-associated agonist of cell death

multiple interactions

[6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] promotes the reaction [BAD protein binds to BCL2 protein]; [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] promotes the reaction [BAD protein binds to BCL2L1 protein]; [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] results in decreased phosphorylation of BAD protein

NCBI chr 1:204,133,502...204,142,829
Ensembl chr 1:204,131,501...204,142,823

G

BCL2 associated X, apoptosis regulator

multiple interactions

[6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] promotes the reaction [BAX protein binds to BCL2 protein]; [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] promotes the reaction [BAX protein binds to BCL2L1 protein]; [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] results in increased expression of BAX protein

NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368

G

BCL2, apoptosis regulator

multiple interactions

[6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] promotes the reaction [BAD protein binds to BCL2 protein]; [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] promotes the reaction [BAX protein binds to BCL2 protein]; [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] results in decreased expression of BCL2 protein

NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

Bcl2-like 1

multiple interactions

[6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] promotes the reaction [BAD protein binds to BCL2L1 protein]; [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] promotes the reaction [BAX protein binds to BCL2L1 protein]; [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] results in decreased expression of BCL2L1 protein

NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479
Ensembl chr 1:141,253,523...141,303,479

G

caspase 3

multiple interactions

[6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] results in increased cleavage of and results in increased activity of CASP3 protein
AH 23848 inhibits the reaction [7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide results in increased cleavage of CASP3 protein]

PMID:19407222 PMID:32115946

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

catenin beta 1

multiple interactions

[6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] promotes the reaction [AXIN1 protein binds to CTNNB1 protein]; [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] promotes the reaction [GSK3B protein binds to CTNNB1 protein]; [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] results in increased degradation of CTNNB1 protein

NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111

G

cytochrome P450, family 19, subfamily a, polypeptide 1

multiple interactions

AH 23848 inhibits the reaction [LEP protein results in increased expression of CYP19A1 mRNA]; AH 23848 inhibits the reaction [LEP protein results in increased expression of CYP19A1 protein]; AH 23848 inhibits the reaction [o,p'-DDT results in increased expression of CYP19A1 mRNA]; AH 23848 inhibits the reaction [o,p'-DDT results in increased expression of CYP19A1 protein]

PMID:20678559 PMID:28571770

NCBI chr 8:54,552,978...54,580,375
Ensembl chr 8:54,553,165...54,580,758

G

cytochrome P450, family 1, subfamily b, polypeptide 1

multiple interactions

AH 23848 inhibits the reaction [Dinoprostone results in increased expression of CYP1B1 mRNA]; AH 23848 inhibits the reaction [Dinoprostone results in increased expression of CYP1B1 protein]

NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917

G

epidermal growth factor receptor

multiple interactions

[6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] inhibits the reaction [EGFR protein modified form binds to SRC protein]; [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] results in decreased phosphorylation of and results in decreased expression of EGFR protein

NCBI chr14:91,176,979...91,349,722
Ensembl chr14:91,177,067...91,344,382

G

early growth response 1

multiple interactions

[6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] results in decreased expression of EGR1 protein

NCBI chr18:26,462,967...26,466,766
Ensembl chr18:26,462,981...26,466,766

G

Fos proto-oncogene, AP-1 transcription factor subunit

multiple interactions

[6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] results in decreased expression of FOS protein

NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036

G

glycogen synthase kinase 3 beta

multiple interactions

[6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] inhibits the reaction [GSK3B protein binds to AKT1 protein]; [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] inhibits the reaction [GSK3B protein binds to MAPK1 protein binds to MAPK3 protein]; [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] promotes the reaction [GSK3B protein binds to CTNNB1 protein]; [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] results in decreased phosphorylation of GSK3B protein

NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646

G

interleukin 1 receptor type 1

multiple interactions

[6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] inhibits the reaction [[ARRB1 protein modified form binds to SRC protein] which binds to IL1R1 protein]; [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] results in decreased expression of IL1R1 protein

NCBI chr 9:42,504,917...42,580,958
Ensembl chr 9:42,504,735...42,579,937

G

Jun proto-oncogene, AP-1 transcription factor subunit

multiple interactions

[6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] results in decreased phosphorylation of JUN protein

NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656

G

leptin

multiple interactions

AH 23848 inhibits the reaction [LEP protein results in increased expression of CYP19A1 mRNA]; AH 23848 inhibits the reaction [LEP protein results in increased expression of CYP19A1 protein]

NCBI chr 4:57,661,127...57,675,262
Ensembl chr 4:57,661,131...57,675,262

G

mitogen activated protein kinase 1

multiple interactions

[6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] inhibits the reaction [GSK3B protein binds to MAPK1 protein binds to MAPK3 protein]; [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] results in decreased phosphorylation of MAPK1 protein

NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616

G

mitogen activated protein kinase 3

multiple interactions

[6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] inhibits the reaction [GSK3B protein binds to MAPK1 protein binds to MAPK3 protein]; [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] results in decreased phosphorylation of MAPK3 protein

NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863

G

matrix metallopeptidase 9

multiple interactions

AH 23848 inhibits the reaction [Lipopolysaccharides results in increased expression of MMP9 protein]

NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120

G

MYC proto-oncogene, bHLH transcription factor

multiple interactions

[6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] results in decreased phosphorylation of MYC protein

NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630

G

nuclear factor kappa B subunit 1

multiple interactions

[6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] results in decreased expression of NFKB1 protein

NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404

G

NFKB inhibitor alpha

multiple interactions

[6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] results in decreased phosphorylation of NFKBIA protein

NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941

G

poly (ADP-ribose) polymerase 1

multiple interactions

[6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] results in increased cleavage of and results in increased activity of PARP1 protein

NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404

G

prostaglandin E receptor 2

multiple interactions

[6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] inhibits the reaction [PTGER2 protein binds to SRC protein]

NCBI chr15:18,215,013...18,228,714
Ensembl chr15:18,217,285...18,228,714

G

prostaglandin E receptor 4

multiple interactions

[6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] inhibits the reaction [PTGER4 protein binds to SRC protein]; AH 23848 binds to and results in decreased activity of PTGER4 protein

PMID:19407222 PMID:30269738

NCBI chr 2:54,330,563...54,347,451
Ensembl chr 2:54,335,424...54,346,670

G

prostaglandin-endoperoxide synthase 2

multiple interactions

AH 23848 inhibits the reaction [o,p'-DDT results in increased expression of PTGS2 mRNA]; AH 23848 inhibits the reaction [o,p'-DDT results in increased expression of PTGS2 protein]

NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188

G

RELA proto-oncogene, NF-kB subunit

multiple interactions

[6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] results in decreased phosphorylation of and results in decreased expression of RELA protein

NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484

G

Sp1 transcription factor

multiple interactions

[6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] results in decreased expression of SP1 protein

NCBI chr 7:133,541,302...133,571,961
Ensembl chr 7:133,541,491...133,571,961

G

SRC proto-oncogene, non-receptor tyrosine kinase

multiple interactions

[6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] inhibits the reaction [[ARRB1 protein modified form binds to SRC protein] which binds to IL1R1 protein]; [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] inhibits the reaction [[ARRB1 protein modified form binds to SRC protein] which binds to TNFRSF1A protein]; [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] inhibits the reaction [ARRB1 protein modified form binds to SRC protein]; [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] inhibits the reaction [EGFR protein modified form binds to SRC protein]; [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] inhibits the reaction [PTGER2 protein binds to SRC protein]; [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] inhibits the reaction [PTGER4 protein binds to SRC protein]; [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] results in decreased phosphorylation of SRC protein

NCBI chr 3:146,091,969...146,139,492
Ensembl chr 3:146,091,841...146,139,476

G

transcription factor 7

multiple interactions

[6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] results in decreased expression of TCF7 protein

NCBI chr10:36,423,443...36,454,350
Ensembl chr10:36,423,445...36,453,535

G

transcription factor 7 like 2

multiple interactions

[6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] results in decreased expression of TCF7L2 protein

NCBI chr 1:254,785,956...254,978,967
Ensembl chr 1:254,786,091...254,978,967

G

tumor necrosis factor

multiple interactions

AH 23848 inhibits the reaction [Lipopolysaccharides results in increased expression of TNF]

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

G

TNF receptor superfamily member 1A

multiple interactions

[6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] inhibits the reaction [[ARRB1 protein modified form binds to SRC protein] which binds to TNFRSF1A protein]; [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] results in decreased expression of TNFRSF1A protein

NCBI chr 4:158,150,815...158,163,592
Ensembl chr 4:158,150,820...158,163,591

Ankaflavin

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

nuclear receptor subfamily 1, group H, member 4

increases expression

ankaflavin results in increased expression of NR1H4 mRNA

NCBI chr 7:23,846,122...23,942,085
Ensembl chr 7:23,846,122...23,942,047

G

peroxisome proliferator activated receptor alpha

increases expression
multiple interactions

ankaflavin results in increased expression of PPARA mRNA
ankaflavin affects the reaction [PPARA protein affects the oxidation of Fatty Acids]; ankaflavin binds to and results in increased activity of PPARA protein

NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346

G

PPARG coactivator 1 alpha

increases expression

ankaflavin results in increased expression of PPARGC1A mRNA

NCBI chr14:58,860,752...59,516,525
Ensembl chr14:58,861,144...59,512,656

azadiradione

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

caspase 3

increases activity

azadiradione results in increased activity of CASP3 protein

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

caspase 8

increases activity

azadiradione results in increased activity of CASP8 protein

NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542

G

caspase 9

increases activity

azadiradione results in increased activity of CASP9 protein

NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626

G

heat shock protein family A (Hsp70) member 1A

increases expression

azadiradione results in increased expression of HSPA1A mRNA

NCBI chr20:3,870,765...3,873,221
Ensembl chr20:3,856,006...3,873,227

Bardoxolone methyl

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

adrenoceptor alpha 1B

decreases activity

bardoxolone methyl results in decreased activity of ADRA1B protein

NCBI chr10:28,255,025...28,373,418
Ensembl chr10:28,255,025...28,312,919

G

adrenoceptor alpha 2C

decreases activity

bardoxolone methyl results in decreased activity of ADRA2C protein

NCBI chr14:75,470,884...75,472,846
Ensembl chr14:75,471,143...75,472,846

G

AKT serine/threonine kinase 1

multiple interactions

bardoxolone methyl inhibits the reaction [Dietary Fats results in decreased phosphorylation of AKT1 protein]

NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921

G

annexin A1

affects expression

bardoxolone methyl affects the expression of ANXA1 mRNA

NCBI chr 1:217,861,175...217,877,205
Ensembl chr 1:217,861,175...217,877,343

G

arginase 1

multiple interactions

bardoxolone methyl inhibits the reaction [Lipopolysaccharides results in increased expression of ARG1 mRNA]

NCBI chr 1:20,475,878...20,488,422
Ensembl chr 1:20,475,968...20,488,422

G

aurora kinase B

decreases activity

bardoxolone methyl results in decreased activity of AURKB protein

NCBI chr10:53,744,290...53,750,831
Ensembl chr10:53,745,142...53,750,837

G

arginine vasopressin receptor 1A

decreases activity

bardoxolone methyl results in decreased activity of AVPR1A protein

NCBI chr 7:58,114,306...58,118,230
Ensembl chr 7:58,114,284...58,122,215

G

beta-1,4-galactosyltransferase 1

increases expression

bardoxolone methyl results in increased expression of B4GALT1 mRNA

NCBI chr 5:55,935,614...55,982,461
Ensembl chr 5:55,935,615...55,982,461

G

Bcl-2 binding component 3

increases expression

bardoxolone methyl results in increased expression of BBC3 mRNA

NCBI chr 1:77,013,281...77,022,509
Ensembl chr 1:77,014,543...77,022,509

G

brain-derived neurotrophic factor

multiple interactions

bardoxolone methyl inhibits the reaction [Dietary Fats results in decreased expression of BDNF protein]

NCBI chr 3:96,165,042...96,215,621
Ensembl chr 3:96,165,042...96,215,615

G

baculoviral IAP repeat-containing 3

increases expression

bardoxolone methyl results in increased expression of BIRC3 mRNA

NCBI chr 8:5,000,844...5,028,470
Ensembl chr 8:5,000,845...5,015,802

G

calcium voltage-gated channel subunit alpha1 C

decreases activity

bardoxolone methyl results in decreased activity of CACNA1C protein

NCBI chr 4:151,764,138...152,379,454
Ensembl chr 4:151,764,138...152,379,648

G

caspase 8

decreases expression

bardoxolone methyl results in decreased expression of CASP8 protein

NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542

G

C-C motif chemokine ligand 11

multiple interactions

bardoxolone methyl inhibits the reaction [Lipopolysaccharides results in increased expression of and results in increased secretion of CCL11 protein]

NCBI chr10:67,028,328...67,032,929
Ensembl chr10:67,028,328...67,032,926

G

C-C motif chemokine ligand 2

multiple interactions
increases expression

bardoxolone methyl inhibits the reaction [Lipopolysaccharides results in increased expression of and results in increased secretion of CCL2 protein]
bardoxolone methyl results in increased expression of CCL2 mRNA

PMID:26918785 PMID:35724838

NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226

G

C-C motif chemokine ligand 20

increases expression

bardoxolone methyl results in increased expression of CCL20 mRNA

NCBI chr 9:84,389,031...84,391,629
Ensembl chr 9:84,388,904...84,391,629

G

C-C motif chemokine ligand 3

multiple interactions

bardoxolone methyl inhibits the reaction [Lipopolysaccharides results in increased expression of and results in increased secretion of CCL3 protein]

NCBI chr10:68,451,388...68,452,938
Ensembl chr10:68,451,388...68,452,938

G

C-C motif chemokine ligand 4

multiple interactions

bardoxolone methyl inhibits the reaction [Lipopolysaccharides results in increased expression of and results in increased secretion of CCL4 protein]

NCBI chr10:68,466,394...68,468,229
Ensembl chr10:68,452,052...68,468,231

G

C-C motif chemokine ligand 5

multiple interactions

bardoxolone methyl inhibits the reaction [Lipopolysaccharides results in increased expression of and results in increased secretion of CCL5 protein]

NCBI chr10:68,322,826...68,327,380
Ensembl chr10:68,322,829...68,327,377

G

C-C motif chemokine receptor 5

multiple interactions

bardoxolone methyl promotes the reaction [Lipopolysaccharides results in increased expression of CCR5 mRNA]

NCBI chr 8:123,752,423...123,757,538
Ensembl chr 8:123,752,325...123,759,260

G

CD163 molecule

multiple interactions

bardoxolone methyl inhibits the reaction [Lipopolysaccharides results in increased expression of CD163 mRNA]; bardoxolone methyl inhibits the reaction [Lipopolysaccharides results in increased expression of CD163 protein]

NCBI chr 4:157,085,080...157,118,470
Ensembl chr 4:157,085,093...157,117,878

G

cholinergic receptor, muscarinic 1

decreases activity

bardoxolone methyl results in decreased activity of CHRM1 protein

NCBI chr 1:205,567,226...205,583,001
Ensembl chr 1:205,567,220...205,582,356

G

cholinergic receptor, muscarinic 2

decreases activity

bardoxolone methyl results in decreased activity of CHRM2 protein

NCBI chr 4:65,015,408...65,149,104
Ensembl chr 4:65,014,144...65,149,103

G

C-type lectin domain containing 10A

multiple interactions

bardoxolone methyl inhibits the reaction [Lipopolysaccharides results in increased expression of CLEC10A mRNA]

NCBI chr10:54,876,244...54,880,439
Ensembl chr10:54,876,260...54,880,435

G

C-X-C motif chemokine ligand 1

increases expression

bardoxolone methyl results in increased expression of CXCL1 mRNA

NCBI chr14:17,193,364...17,195,143
Ensembl chr14:17,193,365...17,195,215

G

C-X-C motif chemokine ligand 2

multiple interactions
increases expression

bardoxolone methyl inhibits the reaction [Lipopolysaccharides results in increased expression of and results in increased secretion of CXCL2 protein]
bardoxolone methyl results in increased expression of CXCL2 mRNA

PMID:26918785 PMID:35724838

NCBI chr14:17,181,030...17,183,075
Ensembl chr14:17,181,062...17,183,075

G

C-X-C motif chemokine ligand 3

increases expression

bardoxolone methyl results in increased expression of CXCL1 mRNA

NCBI chr14:17,287,727...17,289,451
Ensembl chr14:17,270,146...17,289,511

G

DNA-damage inducible transcript 3

increases expression
multiple interactions

bardoxolone methyl results in increased expression of DDIT3 protein
ochratoxin A promotes the reaction [bardoxolone methyl results in increased expression of DDIT3 protein]; Ursolic Acid inhibits the reaction [ochratoxin A promotes the reaction [bardoxolone methyl results in increased expression of DDIT3 protein]]

PMID:35724838 PMID:36587836

NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201

G

DnaJ heat shock protein family (Hsp40) member B1

affects expression

bardoxolone methyl affects the expression of DNAJB1 mRNA

NCBI chr19:24,522,731...24,526,419
Ensembl chr19:24,522,717...24,526,458

G

dopamine receptor D1

decreases activity

bardoxolone methyl results in decreased activity of DRD1 protein

NCBI chr17:10,540,440...10,544,971
Ensembl chr17:10,540,558...10,545,002

G

dopamine receptor D2

decreases activity

bardoxolone methyl results in decreased activity of DRD2 protein

NCBI chr 8:49,708,927...49,772,876
Ensembl chr 8:49,708,927...49,772,875

G

endothelin 1

increases expression

bardoxolone methyl results in increased expression of EDN1 mRNA

NCBI chr17:22,454,924...22,460,812
Ensembl chr17:22,454,420...22,460,885

G

egl-9 family hypoxia-inducible factor 3

affects expression

bardoxolone methyl affects the expression of EGLN3 mRNA

NCBI chr 6:71,650,297...71,675,766
Ensembl chr 6:71,650,297...71,675,766

G

eukaryotic translation initiation factor 4E binding protein 1

multiple interactions

bardoxolone methyl results in decreased expression of and results in decreased phosphorylation of EIF4EBP1 protein

NCBI chr16:64,792,595...64,805,984
Ensembl chr16:64,790,226...64,805,984

G

fatty acid synthase

decreases expression

bardoxolone methyl results in decreased expression of FASN mRNA

NCBI chr10:106,072,093...106,090,259
Ensembl chr10:106,072,091...106,090,261

G

flavin containing dimethylaniline monoxygenase 2

increases expression

bardoxolone methyl results in increased expression of FMO2 mRNA

NCBI chr13:75,221,149...75,244,377
Ensembl chr13:75,224,402...75,244,308

G

forkhead box O1

multiple interactions

bardoxolone methyl inhibits the reaction [Dietary Fats results in increased expression of and results in decreased phosphorylation of FOXO1 protein]

NCBI chr 2:136,312,168...136,390,603
Ensembl chr 2:136,312,168...136,387,790

G

growth arrest and DNA-damage-inducible, alpha

affects expression

bardoxolone methyl affects the expression of GADD45A mRNA

NCBI chr 4:96,154,789...96,157,091
Ensembl chr 4:96,154,789...96,157,115

G

glutamate-cysteine ligase, catalytic subunit

increases expression
decreases expression

bardoxolone methyl results in increased expression of GCLC mRNA; bardoxolone methyl results in increased expression of GCLC protein
bardoxolone methyl results in decreased expression of GCLC mRNA

PMID:27480280 PMID:34480604 PMID:35724838

NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544

G

glutamate cysteine ligase, modifier subunit

increases expression
decreases expression

bardoxolone methyl results in increased expression of GCLM; bardoxolone methyl results in increased expression of GCLM mRNA
bardoxolone methyl results in decreased expression of GCLM mRNA

PMID:21723306 PMID:34480604 PMID:35724838

NCBI chr 2:210,347,482...210,367,537
Ensembl chr 2:210,347,482...210,367,535

G

glutathione peroxidase 2

affects expression

bardoxolone methyl affects the expression of GPX2 mRNA

NCBI chr 6:95,493,589...95,496,877
Ensembl chr 6:95,493,589...95,496,877

G

glycogen synthase kinase 3 beta

multiple interactions
increases phosphorylation

GSK3B protein mutant form inhibits the reaction [bardoxolone methyl results in increased expression of HMOX1 protein]; GSK3B protein mutant form inhibits the reaction [bardoxolone methyl results in increased phosphorylation of GSK3B protein]

NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646

G

glutathione S-transferase alpha 1

decreases expression

bardoxolone methyl results in decreased expression of GSTA1 mRNA

NCBI chr 9:23,703,476...23,720,121
Ensembl chr 9:23,703,477...23,720,121

G

glutathione S-transferase pi 1

increases expression

bardoxolone methyl results in increased expression of GSTP1 mRNA

NCBI chr 1:201,337,762...201,340,230
Ensembl chr 1:201,321,672...201,340,226

G

heme oxygenase 1

multiple interactions
decreases expression
increases expression

bardoxolone methyl inhibits the reaction [eriodictyol results in decreased expression of HMOX1 protein]; GSK3B protein mutant form inhibits the reaction [bardoxolone methyl results in increased expression of HMOX1 protein]; NFE2L2 protein affects the reaction [bardoxolone methyl results in increased expression of HMOX1 protein]
bardoxolone methyl results in decreased expression of HMOX1 mRNA
bardoxolone methyl results in increased expression of HMOX1 mRNA; bardoxolone methyl results in increased expression of HMOX1 protein
[bardoxolone methyl co-treated with aristolochic acid I] results in increased expression of HMOX1 mRNA; bardoxolone methyl promotes the reaction [aristolochic acid I results in increased expression of HMOX1 protein]

PMID:21289052 PMID:24530882 PMID:25246272 PMID:28790194 PMID:34480604 More...

NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079

G

histamine receptor H 1

decreases activity

bardoxolone methyl results in decreased activity of HRH1 protein

NCBI chr 4:147,564,963...147,649,353
Ensembl chr 4:147,645,995...147,647,455

G

heat shock transcription factor 1

increases activity

bardoxolone methyl results in increased activity of HSF1 protein

NCBI chr 7:108,196,040...108,223,011
Ensembl chr 7:108,196,056...108,223,011

G

heat shock protein family A (Hsp70) member 5

increases expression
multiple interactions

bardoxolone methyl results in increased expression of HSPA5 protein
ochratoxin A promotes the reaction [bardoxolone methyl results in increased expression of HSPA5 protein]

PMID:35724838 PMID:36587836

NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891

G

5-hydroxytryptamine receptor 2A

decreases activity

bardoxolone methyl results in decreased activity of HTR2A protein

NCBI chr15:49,950,035...50,022,188
Ensembl chr15:49,950,804...50,020,928

G

5-hydroxytryptamine receptor 2C

decreases activity

bardoxolone methyl results in decreased activity of HTR2C protein

NCBI chr X:110,640,777...110,870,288
Ensembl chr X:110,641,153...110,870,287

G

intercellular adhesion molecule 1

multiple interactions

bardoxolone methyl inhibits the reaction [IL1B protein results in increased expression of ICAM1 protein]; bardoxolone methyl inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]

NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438

G

interferon gamma

multiple interactions

bardoxolone methyl inhibits the reaction [IFNG protein results in increased expression of NOS2]

NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375

G

interleukin 10

multiple interactions

bardoxolone methyl inhibits the reaction [Lipopolysaccharides results in increased expression of and results in increased secretion of IL10 protein]; bardoxolone methyl inhibits the reaction [Lipopolysaccharides results in increased expression of IL10 mRNA]

NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313

G

interleukin 17A

multiple interactions

bardoxolone methyl inhibits the reaction [Lipopolysaccharides results in increased expression of and results in increased secretion of IL17A protein]

NCBI chr 9:23,144,402...23,147,889
Ensembl chr 9:23,144,402...23,147,889

G

interleukin 1 beta

multiple interactions

bardoxolone methyl inhibits the reaction [IL1B protein affects the localization of NFKBIA protein]; bardoxolone methyl inhibits the reaction [IL1B protein affects the localization of RELA protein]; bardoxolone methyl inhibits the reaction [IL1B protein results in increased expression of ICAM1 protein]; bardoxolone methyl inhibits the reaction [IL1B protein results in increased expression of TNFAIP3 protein]

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

interleukin 1 receptor type 1

affects expression

bardoxolone methyl affects the expression of IL1R1 mRNA

NCBI chr 9:42,504,917...42,580,958
Ensembl chr 9:42,504,735...42,579,937

G

interleukin 6

multiple interactions

bardoxolone methyl inhibits the reaction [Dietary Fats results in increased expression of IL6 protein]; bardoxolone methyl promotes the reaction [Lipopolysaccharides results in increased expression of and results in increased secretion of IL6 protein]

PMID:26918785 PMID:27417254

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

insulin 2

multiple interactions

bardoxolone methyl inhibits the reaction [INS protein results in increased phosphorylation of RPS6 protein]

NCBI chr 1:197,843,277...197,992,522
Ensembl chr 1:197,843,281...197,864,775

G

interferon regulatory factor 5

multiple interactions

bardoxolone methyl promotes the reaction [Lipopolysaccharides results in increased expression of IRF5 mRNA]

NCBI chr 4:58,127,577...58,140,665
Ensembl chr 4:58,127,640...58,139,267

G

Janus kinase 2

multiple interactions

bardoxolone methyl inhibits the reaction [Dietary Fats results in decreased phosphorylation of JAK2 protein]

NCBI chr 1:226,995,334...227,054,381
Ensembl chr 1:226,995,334...227,054,189

G

Kelch-like ECH-associated protein 1

increases expression
decreases expression
multiple interactions

bardoxolone methyl results in increased expression of KEAP1 protein
bardoxolone methyl results in decreased expression of KEAP1 mRNA
bardoxolone methyl inhibits the reaction [aristolochic acid I results in increased expression of KEAP1 protein]

PMID:24530882 PMID:27358234 PMID:35724838

NCBI chr 8:19,768,375...19,777,862
Ensembl chr 8:19,768,375...19,777,862

G

leptin

multiple interactions

bardoxolone methyl inhibits the reaction [Dietary Fats results in decreased susceptibility to LEP protein]; bardoxolone methyl inhibits the reaction [Dietary Fats results in increased expression of LEP protein]

NCBI chr 4:57,661,127...57,675,262
Ensembl chr 4:57,661,131...57,675,262

G

LIF, interleukin 6 family cytokine

multiple interactions

bardoxolone methyl inhibits the reaction [Lipopolysaccharides results in increased expression of and results in increased secretion of LIF protein]

NCBI chr14:79,131,049...79,140,486
Ensembl chr14:79,134,574...79,140,482

G

lon peptidase 1, mitochondrial

decreases expression

bardoxolone methyl results in decreased expression of LONP1 protein

NCBI chr 9:1,447,444...1,459,771
Ensembl chr 9:1,447,447...1,459,771

G

MAF bZIP transcription factor G

affects expression
decreases expression

bardoxolone methyl affects the expression of MAFG mRNA
bardoxolone methyl results in decreased expression of MAFG mRNA

PMID:34480604 PMID:35724838

NCBI chr10:105,903,307...105,911,808
Ensembl chr10:105,903,237...105,912,026

G

mitofusin 1

decreases expression

bardoxolone methyl results in decreased expression of MFN1 protein

NCBI chr 2:115,313,380...115,359,651
Ensembl chr 2:115,313,401...115,359,640

G

mitofusin 2

decreases expression

bardoxolone methyl results in decreased expression of MFN2 protein

NCBI chr 5:158,304,285...158,335,502
Ensembl chr 5:158,304,287...158,335,342

G

mannose receptor, C type 1

multiple interactions

bardoxolone methyl inhibits the reaction [Lipopolysaccharides results in increased expression of MRC1 protein]

NCBI chr17:77,249,187...77,330,857
Ensembl chr17:77,249,187...77,330,857

G

mechanistic target of rapamycin kinase

decreases phosphorylation

bardoxolone methyl results in decreased phosphorylation of MTOR protein

NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311

G

NFE2 like bZIP transcription factor 2

increases expression
multiple interactions
increases localization
decreases response to substance
increases activity

bardoxolone methyl results in increased expression of NFE2L2 mRNA; bardoxolone methyl results in increased expression of NFE2L2 protein
bardoxolone methyl inhibits the reaction [aristolochic acid I results in decreased expression of and affects the localization of NFE2L2 protein]; bardoxolone methyl inhibits the reaction [aristolochic acid I results in decreased expression of NFE2L2 mRNA]
bardoxolone methyl results in increased localization of NFE2L2 protein
NFE2L2 gene mutant form results in decreased susceptibility to bardoxolone methyl
bardoxolone methyl inhibits the reaction [eriodictyol results in decreased phosphorylation of NFE2L2 protein]; bardoxolone methyl results in increased expression of and affects the localization of NFE2L2 protein; NFE2L2 promotes the reaction [bardoxolone methyl results in increased expression of SRXN1 protein]; NFE2L2 protein affects the reaction [bardoxolone methyl results in increased expression of HMOX1 protein]
bardoxolone methyl results in increased activity of NFE2L2 protein

PMID:21289052 PMID:21723306 PMID:24530882 PMID:24798383 PMID:25246272 More...

NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737

G

NFKB inhibitor alpha

multiple interactions

bardoxolone methyl inhibits the reaction [Dietary Fats results in decreased expression of NFKBIA protein]
bardoxolone methyl inhibits the reaction [IL1B protein affects the localization of NFKBIA protein]; bardoxolone methyl inhibits the reaction [TNF protein affects the localization of NFKBIA protein]

PMID:25637688 PMID:35724838

NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941

G

NFKB inhibitor epsilon

increases expression

bardoxolone methyl results in increased expression of NFKBIE mRNA

NCBI chr 9:15,443,600...15,450,437
Ensembl chr 9:15,436,941...15,450,437

G

nitric oxide synthase 2

multiple interactions

bardoxolone methyl inhibits the reaction [IFNG protein results in increased expression of NOS2]

NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210

G

NAD(P)H quinone dehydrogenase 1

increases expression
multiple interactions
decreases expression
increases activity

bardoxolone methyl results in increased expression of NQO1 mRNA; bardoxolone methyl results in increased expression of NQO1 protein
bardoxolone methyl inhibits the reaction [eriodictyol results in decreased expression of NQO1 protein]
bardoxolone methyl results in decreased expression of NQO1 mRNA
bardoxolone methyl results in increased activity of NQO1 protein
[bardoxolone methyl co-treated with aristolochic acid I] results in increased expression of NQO1 mRNA; [bardoxolone methyl co-treated with aristolochic acid I] results in increased expression of NQO1 protein

PMID:24530882 PMID:27480280 PMID:28790194 PMID:34480604 PMID:35724838 More...

NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557

G

oxidized low density lipoprotein receptor 1

increases expression

bardoxolone methyl results in increased expression of OLR1 mRNA

NCBI chr 4:162,926,436...162,949,057
Ensembl chr 4:162,926,439...162,948,523

G

OPA1, mitochondrial dynamin like GTPase

increases cleavage

bardoxolone methyl results in increased cleavage of OPA1 protein

NCBI chr11:71,108,100...71,185,170
Ensembl chr11:71,109,873...71,185,109

G

opioid receptor, kappa 1

decreases activity

bardoxolone methyl results in decreased activity of OPRK1 protein

NCBI chr 5:13,860,016...13,877,823
Ensembl chr 5:13,860,021...13,877,823

G

opioid receptor, mu 1

decreases activity

bardoxolone methyl results in decreased activity of OPRM1 protein

NCBI chr 1:43,160,057...43,413,409
Ensembl chr 1:43,160,057...43,413,409

G

poly (ADP-ribose) polymerase 1

increases cleavage

bardoxolone methyl results in increased cleavage of PARP1 protein

PMID:17363558 PMID:25246272

NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404

G

phosphodiesterase 4B

decreases activity

bardoxolone methyl results in decreased activity of PDE4B protein

NCBI chr 5:116,799,819...117,369,155
Ensembl chr 5:116,799,971...117,367,696

G

platelet derived growth factor subunit B

increases expression

bardoxolone methyl results in increased expression of PDGFB mRNA

NCBI chr 7:111,539,444...111,557,984
Ensembl chr 7:111,540,345...111,557,984

G

phosphofructokinase, muscle

decreases expression

bardoxolone methyl results in decreased expression of PFKM protein

NCBI chr 7:129,221,679...129,259,192
Ensembl chr 7:129,221,653...129,259,192

G

pyruvate kinase M1/2

decreases expression

bardoxolone methyl results in decreased expression of PKM protein

NCBI chr 8:60,057,629...60,079,600
Ensembl chr 8:60,057,402...60,079,599

G

plasminogen activator, urokinase

increases expression

bardoxolone methyl results in increased expression of PLAU mRNA

NCBI chr15:3,456,230...3,462,732
Ensembl chr15:3,456,232...3,462,775

G

peroxisome proliferator-activated receptor gamma

increases expression

bardoxolone methyl results in increased expression of PPARG mRNA; bardoxolone methyl results in increased expression of PPARG protein

NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468

G

protein kinase AMP-activated non-catalytic subunit gamma 2

affects expression

bardoxolone methyl affects the expression of PRKAG2 mRNA

NCBI chr 4:10,010,890...10,252,155
Ensembl chr 4:10,010,890...10,252,142

G

protein tyrosine phosphatase, non-receptor type 1

multiple interactions

bardoxolone methyl inhibits the reaction [Dietary Fats results in increased expression of PTPN1 protein]

NCBI chr 3:156,638,811...156,687,503
Ensembl chr 3:156,638,769...156,687,504

G

retinoic acid receptor, alpha

affects expression

bardoxolone methyl affects the expression of RARA mRNA

NCBI chr10:83,883,490...83,928,932
Ensembl chr10:83,893,384...83,928,142

G

RELA proto-oncogene, NF-kB subunit

multiple interactions

bardoxolone methyl inhibits the reaction [IL1B protein affects the localization of RELA protein]; bardoxolone methyl inhibits the reaction [TNF protein affects the localization of RELA protein]

NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484

G

ribosomal protein S6

multiple interactions
decreases expression

bardoxolone methyl inhibits the reaction [INS protein results in increased phosphorylation of RPS6 protein]
bardoxolone methyl results in decreased expression of RPS6 protein

PMID:28790194 PMID:35929395

NCBI chr 5:101,371,716...101,374,576
Ensembl chr 5:101,371,136...101,374,602
Ensembl chr 5:101,371,136...101,374,602

G

ribosomal protein S6 kinase B1

decreases phosphorylation

bardoxolone methyl results in decreased phosphorylation of RPS6KB1 protein

NCBI chr10:71,323,777...71,367,908
Ensembl chr10:71,323,777...71,367,908

G

scavenger receptor class B, member 1

affects expression

bardoxolone methyl affects the expression of SCARB1 mRNA

NCBI chr12:31,296,143...31,362,649
Ensembl chr12:31,296,156...31,362,647

G

SH3-domain binding protein 5

affects expression

bardoxolone methyl affects the expression of SH3BP5 mRNA

NCBI chr16:6,583,462...6,678,344
Ensembl chr16:6,583,465...6,698,975

G

sigma non-opioid intracellular receptor 1

multiple interactions
decreases expression

Ursolic Acid inhibits the reaction [bardoxolone methyl results in decreased expression of SIGMAR1 protein]

NCBI chr 5:56,904,155...56,907,012
Ensembl chr 5:56,904,159...56,907,017

G

solute carrier family 1 member 5

decreases expression
decreases glycosylation

bardoxolone methyl results in decreased expression of SLC1A5 protein
bardoxolone methyl results in decreased glycosylation of SLC1A5 protein

NCBI chr 1:77,456,849...77,470,952
Ensembl chr 1:77,456,694...77,470,952

G

solute carrier family 3 member 2

decreases expression

bardoxolone methyl results in decreased expression of SLC3A2 mRNA

NCBI chr 1:205,604,468...205,618,931
Ensembl chr 1:205,604,468...205,618,931

G

solute carrier family 47 member 1

increases expression

bardoxolone methyl results in increased expression of SLC47A1 mRNA; bardoxolone methyl results in increased expression of SLC47A1 protein

NCBI chr10:46,034,115...46,088,617
Ensembl chr10:46,034,122...46,087,637

G

suppressor of cytokine signaling 3

multiple interactions

bardoxolone methyl inhibits the reaction [Lipopolysaccharides results in increased expression of SOCS3 mRNA]

NCBI chr10:103,193,909...103,197,322
Ensembl chr10:103,193,537...103,197,787

G

sequestosome 1

affects expression
decreases expression

bardoxolone methyl affects the expression of SQSTM1 mRNA
bardoxolone methyl results in decreased expression of SQSTM1 mRNA

PMID:34480604 PMID:35724838

NCBI chr10:34,525,517...34,536,670
Ensembl chr10:34,525,519...34,536,673

G

sulfiredoxin 1

increases expression
decreases expression
multiple interactions

bardoxolone methyl results in increased expression of SRXN1 protein
bardoxolone methyl results in decreased expression of SRXN1 mRNA
bardoxolone methyl results in increased expression of SRXN1 mRNA; bardoxolone methyl results in increased expression of SRXN1 protein
NFE2L2 promotes the reaction [bardoxolone methyl results in increased expression of SRXN1 protein]

PMID:27358234 PMID:34480604 PMID:35724838

NCBI chr 3:140,604,490...140,610,050
Ensembl chr 3:140,599,608...140,628,448

G

signal transducer and activator of transcription 3

multiple interactions
decreases phosphorylation

[bardoxolone methyl co-treated with Dietary Fats] results in decreased expression of STAT3 protein; bardoxolone methyl inhibits the reaction [Dietary Fats results in increased expression of STAT3 protein]
bardoxolone methyl results in decreased phosphorylation of STAT3 protein

PMID:17363558 PMID:25637688 PMID:27417254

NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057

G

tachykinin receptor 1

decreases activity

bardoxolone methyl results in decreased activity of TACR1 protein

NCBI chr 4:114,920,844...115,089,733
Ensembl chr 4:114,920,844...115,089,733

G

transporter 1, ATP binding cassette subfamily B member

increases expression

bardoxolone methyl results in increased expression of TAP1 mRNA

NCBI chr20:4,656,262...4,666,634
Ensembl chr20:4,656,263...4,666,901

G

tyrosine hydroxylase

multiple interactions

bardoxolone methyl inhibits the reaction [Dietary Fats results in decreased phosphorylation of TH protein]

NCBI chr 1:198,071,500...198,078,832
Ensembl chr 1:198,071,503...198,109,767

G

thyroid hormone responsive

decreases expression

bardoxolone methyl results in decreased expression of THRSP mRNA

NCBI chr 1:151,723,415...151,727,740
Ensembl chr 1:151,723,086...151,728,075

G

tumor necrosis factor

multiple interactions

bardoxolone methyl inhibits the reaction [TNF protein affects the localization of NFKBIA protein]; bardoxolone methyl inhibits the reaction [TNF protein affects the localization of RELA protein]; bardoxolone methyl inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]; bardoxolone methyl inhibits the reaction [TNF protein results in increased expression of TNFAIP3 protein]; bardoxolone methyl promotes the reaction [Lipopolysaccharides results in increased expression of and results in increased secretion of TNF protein]; bardoxolone methyl promotes the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]
[bardoxolone methyl co-treated with Dietary Fats] results in decreased expression of TNF protein; bardoxolone methyl inhibits the reaction [Dietary Fats results in increased expression of TNF protein]; bardoxolone methyl inhibits the reaction [Dietary Fats results in increased expression of TNF]; bardoxolone methyl promotes the reaction [Lipopolysaccharides results in increased expression of and results in increased secretion of TNF protein]; bardoxolone methyl promotes the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]

PMID:25637688 PMID:26612656 PMID:26918785 PMID:27417254 PMID:35724838

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

G

TNF alpha induced protein 3

increases expression
multiple interactions

bardoxolone methyl results in increased expression of TNFAIP3 mRNA; bardoxolone methyl results in increased expression of TNFAIP3 protein
bardoxolone methyl inhibits the reaction [IL1B protein results in increased expression of TNFAIP3 protein]; bardoxolone methyl inhibits the reaction [TNF protein results in increased expression of TNFAIP3 protein]

NCBI chr 1:13,709,211...13,724,291
Ensembl chr 1:13,709,206...13,725,282

G

TNF receptor superfamily member 9

increases expression

bardoxolone methyl results in increased expression of TNFRSF9 mRNA

NCBI chr 5:161,381,662...161,408,003
Ensembl chr 5:161,381,662...161,408,000

G

tribbles pseudokinase 3

decreases expression

bardoxolone methyl results in decreased expression of TRIB3 mRNA

NCBI chr 3:140,809,634...140,815,230
Ensembl chr 3:140,809,043...140,814,497

G

thioredoxin reductase 1

increases expression
decreases expression

bardoxolone methyl results in increased expression of TXNRD1 mRNA
bardoxolone methyl results in decreased expression of TXNRD1 mRNA

PMID:34480604 PMID:35724838

NCBI chr 7:20,830,042...20,914,990
Ensembl chr 7:20,830,045...20,907,863

G

uncoupling protein 2

multiple interactions

bardoxolone methyl inhibits the reaction [Dietary Fats results in decreased expression of UCP2 protein]

NCBI chr 1:154,839,242...154,845,612
Ensembl chr 1:154,839,209...154,845,611

G

vascular cell adhesion molecule 1

increases expression

bardoxolone methyl results in increased expression of VCAM1 mRNA

NCBI chr 2:204,038,120...204,057,852
Ensembl chr 2:204,038,114...204,057,958

G

vascular endothelial growth factor A

multiple interactions
decreases expression

bardoxolone methyl inhibits the reaction [Lipopolysaccharides results in increased expression of and results in increased secretion of VEGFA protein]; bardoxolone methyl inhibits the reaction [Lipopolysaccharides results in increased expression of VEGFA mRNA]
bardoxolone methyl results in decreased expression of VEGFA mRNA

PMID:26918785 PMID:35724838

NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641

G

zinc finger AN1-type containing 2A

affects expression
decreases expression

bardoxolone methyl affects the expression of ZFAND2A mRNA
bardoxolone methyl results in decreased expression of ZFAND2A mRNA

PMID:34480604 PMID:35724838

NCBI chr12:15,161,601...15,172,679
Ensembl chr12:15,161,639...15,172,677

beta-damascenone

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

calmodulin-like 5

increases expression

beta-damascenone results in increased expression of CALM4 mRNA

NCBI chr17:66,394,433...66,395,352

G

caspase 14

increases expression
affects localization

beta-damascenone results in increased expression of CASP14 mRNA
beta-damascenone affects the localization of CASP14 protein

NCBI chr 7:10,929,759...10,932,591
Ensembl chr 7:10,926,725...10,933,405

G

carboxylesterase 3a

increases expression

beta-damascenone results in increased expression of CES3 mRNA

NCBI chr19:32,992,386...33,000,562

G

chloride channel accessory 1

increases expression

beta-damascenone results in increased expression of CLCA1 mRNA

NCBI chr 2:233,938,677...233,964,369
Ensembl chr 2:233,938,677...233,964,369

G

chloride channel accessory 2

increases expression

beta-damascenone results in increased expression of CLCA2 mRNA

NCBI chr 2:233,993,619...234,022,691
Ensembl chr 2:233,995,078...234,022,199

G

cytochrome P450, family 17, subfamily a, polypeptide 1

increases expression

beta-damascenone results in increased expression of CYP17A1 mRNA

NCBI chr 1:245,535,462...245,543,148
Ensembl chr 1:245,535,462...245,541,573

G

Fc gamma binding protein

increases expression

beta-damascenone results in increased expression of FCGBP mRNA

NCBI chr 1:83,374,979...83,413,082
Ensembl chr 1:83,372,127...83,413,083

G

filaggrin

increases expression

beta-damascenone results in increased expression of FLG mRNA; beta-damascenone results in increased expression of FLG protein

NCBI chr 2:178,884,793...178,912,986

G

hornerin

increases expression

beta-damascenone results in increased expression of HRNR mRNA

G

interleukin 20 receptor subunit alpha

increases expression

beta-damascenone results in increased expression of IL20RA mRNA

NCBI chr 1:14,424,215...14,494,226
Ensembl chr 1:14,451,228...14,493,602

G

interleukin 36 receptor antagonist

increases expression

beta-damascenone results in increased expression of IL36RN mRNA

NCBI chr 3:7,044,419...7,051,016
Ensembl chr 3:7,044,406...7,051,016

G

keratin 1

increases expression

beta-damascenone results in increased expression of KRT1 mRNA

NCBI chr 7:132,976,618...132,981,844
Ensembl chr 7:132,976,620...132,981,844

G

keratin 10

increases expression

beta-damascenone results in increased expression of KRT10 mRNA

NCBI chr10:84,338,695...84,343,279
Ensembl chr10:84,338,706...84,343,701

G

late cornified envelope 1B

increases expression

beta-damascenone results in increased expression of LCE1B mRNA

NCBI chr 2:178,255,351...178,257,533
Ensembl chr 2:178,256,213...178,257,985

G

late cornified envelope 1F

increases expression

beta-damascenone results in increased expression of LCE1F mRNA

NCBI chr 2:178,305,786...178,307,372
Ensembl chr 2:178,305,786...178,307,372

G

lipase, family member M

increases expression

beta-damascenone results in increased expression of LIPM mRNA

NCBI chr 1:231,618,145...231,637,599
Ensembl chr 1:231,618,284...231,637,410

G

loricrin cornified envelope precursor protein

increases expression

beta-damascenone results in increased expression of LORICRIN mRNA

NCBI chr 2:177,558,062...177,560,960
Ensembl chr 2:177,558,252...177,559,807

G

otopetrin 3

increases expression

beta-damascenone results in increased expression of OTOP3 mRNA

NCBI chr10:100,577,346...100,588,729
Ensembl chr10:100,577,392...100,588,726

G

phospholipase A2, group IVF

increases expression

beta-damascenone results in increased expression of PLA2G4F mRNA

NCBI chr 3:107,249,053...107,266,201
Ensembl chr 3:107,250,075...107,264,689

G

phosphatidylinositol-specific phospholipase C, X domain containing 1

increases expression

beta-damascenone results in increased expression of PLCXD1 mRNA

NCBI chr12:46,578,917...46,582,181
Ensembl chr12:46,579,225...46,582,392

G

short chain dehydrogenase/reductase family 16C, member 5

increases expression

beta-damascenone results in increased expression of SDR16C5 mRNA

NCBI chr 5:17,018,813...17,043,974
Ensembl chr 5:17,018,813...17,040,970

G

sushi domain containing 2

increases expression

beta-damascenone results in increased expression of SUSD2 mRNA

NCBI chr20:13,017,516...13,024,820
Ensembl chr20:13,017,477...13,024,903

G

transmembrane serine protease 4

increases expression

beta-damascenone results in increased expression of TMPRSS4 mRNA

NCBI chr 8:45,475,819...45,508,409
Ensembl chr 8:45,476,053...45,508,409

camphor

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

acetyl-CoA carboxylase alpha

multiple interactions

[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in decreased expression of ACACA mRNA

NCBI chr10:69,014,261...69,276,453
Ensembl chr10:69,014,170...69,276,457

G

acetyl-CoA carboxylase beta

multiple interactions

[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of ACACB mRNA

NCBI chr12:42,365,800...42,477,651
Ensembl chr12:42,366,548...42,457,655

G

ATP citrate lyase

multiple interactions

[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in decreased expression of ACLY mRNA

NCBI chr10:85,412,045...85,464,253
Ensembl chr10:85,412,049...85,463,320

G

actin alpha 2, smooth muscle

multiple interactions

[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in decreased expression of ACTA2 mRNA

NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554

G

aryl hydrocarbon receptor

multiple interactions

[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of AHR mRNA

NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568

G

AKT serine/threonine kinase 1

multiple interactions

[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of AKT1 mRNA

NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921

G

catalase

multiple interactions

[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in decreased expression of CAT mRNA

NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478

G

cellular communication network factor 2

multiple interactions

[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of CTGF mRNA

NCBI chr 1:20,802,199...20,805,315
Ensembl chr 1:20,802,199...20,805,734

G

collagen type I alpha 1 chain

multiple interactions

[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in decreased expression of COL1A1 mRNA

NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624

G

collagen type I alpha 2 chain

affects expression

Camphor analog affects the expression of COL1A2 mRNA

NCBI chr 4:32,563,938...32,598,868
Ensembl chr 4:32,563,381...32,598,867

G

carnitine palmitoyltransferase 1A

multiple interactions

[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of CPT1A mRNA

NCBI chr 1:200,564,634...200,627,059
Ensembl chr 1:200,565,613...200,627,055

G

carnitine palmitoyltransferase 2

multiple interactions

[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of CPT2 mRNA

NCBI chr 5:122,664,677...122,682,126
Ensembl chr 5:122,664,677...122,682,095

G

cytochrome P450, family 1, subfamily a, polypeptide 1

multiple interactions

[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of CYP1A1 mRNA

NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125

G

cytochrome P450, family 2, subfamily b, polypeptide 1

decreases activity

Camphor results in decreased activity of CYP2B1 protein

NCBI chr 1:81,518,387...81,544,999
Ensembl chr 1:81,518,408...81,542,052

G

cytochrome P450, family 2, subfamily b, polypeptide 3

multiple interactions

Camphor inhibits the reaction [CYP2B6 protein results in increased hydrolysis of Bupropion]

NCBI chr 1:81,652,762...81,732,153
Ensembl chr 1:81,652,787...81,732,143

G

diacylglycerol O-acyltransferase 1

multiple interactions

[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of DGAT1 mRNA

NCBI chr 7:108,223,860...108,235,413
Ensembl chr 7:108,218,524...108,234,299

G

estrogen receptor 1

multiple interactions

Camphor binds to and results in increased activity of ESR1 protein

NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002

G

fatty acid synthase

multiple interactions

[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of FASN mRNA

NCBI chr10:106,072,093...106,090,259
Ensembl chr10:106,072,091...106,090,261

G

forkhead box O1

multiple interactions

[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of FOXO1 mRNA

NCBI chr 2:136,312,168...136,390,603
Ensembl chr 2:136,312,168...136,387,790

G

gamma-aminobutyric acid type A receptor subunit alpha 1

multiple interactions

Camphor promotes the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA1 protein binds to GABRB2 protein binds to GABRG2 protein]]

NCBI chr10:26,595,151...26,650,611
Ensembl chr10:26,595,160...26,650,864

G

gamma-aminobutyric acid type A receptor subunit beta 2

multiple interactions

Camphor promotes the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA1 protein binds to GABRB2 protein binds to GABRG2 protein]]

NCBI chr10:26,936,592...27,156,141
Ensembl chr10:26,936,551...27,151,251

G

gamma-aminobutyric acid type A receptor subunit gamma 2

multiple interactions

Camphor promotes the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA1 protein binds to GABRB2 protein binds to GABRG2 protein]]

NCBI chr10:26,374,693...26,463,937
Ensembl chr10:26,374,694...26,464,346

G

glutathione peroxidase 1

multiple interactions

[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of GPX1 mRNA

NCBI chr 8:109,026,905...109,028,031
Ensembl chr 8:109,026,905...109,028,024

G

glutathione-disulfide reductase

multiple interactions

[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of GSR mRNA

NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661

G

malonyl-CoA decarboxylase

multiple interactions

[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of MLYCD mRNA

NCBI chr19:47,447,931...47,463,794
Ensembl chr19:47,447,970...47,463,793

G

myeloperoxidase

multiple interactions

Camphor inhibits the reaction [cinnamaldehyde results in increased activity of MPO protein]

NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819

G

NFE2 like bZIP transcription factor 2

multiple interactions

[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of NFE2L2 mRNA

NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737

G

nuclear factor kappa B subunit 1

multiple interactions

[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of NFKB1 mRNA

NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404

G

progesterone receptor

multiple interactions

Camphor binds to and results in decreased activity of PGR protein

NCBI chr 8:6,072,673...6,131,552
Ensembl chr 8:6,072,673...6,131,344

G

peroxisome proliferator activated receptor alpha

multiple interactions

[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of PPARA mRNA

NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346

G

prostaglandin-endoperoxide synthase 1

multiple interactions

[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of PTGS1 mRNA

NCBI chr 3:19,584,015...19,605,589
Ensembl chr 3:19,584,015...19,605,586

G

RUNX family transcription factor 2

affects expression

Camphor analog affects the expression of RUNX2 mRNA

NCBI chr 9:16,167,504...16,492,826
Ensembl chr 9:16,167,482...16,492,167

G

snail family transcriptional repressor 1

multiple interactions

[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of SNAI1 mRNA

NCBI chr 3:156,248,479...156,252,969
Ensembl chr 3:156,248,485...156,252,969

G

superoxide dismutase 1

multiple interactions

[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of SOD1 mRNA

NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249

G

secreted protein acidic and cysteine rich

affects expression

Camphor analog affects the expression of SPARC mRNA

NCBI chr10:39,516,394...39,538,252
Ensembl chr10:39,516,406...39,538,396

G

transforming growth factor, beta 1

multiple interactions

[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in decreased expression of TGFB1 mRNA

NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847

G

transient receptor potential cation channel, subfamily V, member 1

multiple interactions

Lidocaine promotes the reaction [Camphor results in increased activity of TRPV1 protein]

NCBI chr10:57,851,428...57,876,513
Ensembl chr10:57,851,428...57,876,513

G

transient receptor potential cation channel, subfamily V, member 3

increases activity
multiple interactions

Camphor results in increased activity of TRPV3 protein
isopentenyl pyrophosphate inhibits the reaction [Camphor results in increased activity of TRPV3 protein]

NCBI chr10:57,883,546...57,915,865
Ensembl chr10:57,883,546...57,913,296

G

zinc finger E-box binding homeobox 1

multiple interactions

[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of ZEB1 mRNA

NCBI chr17:51,948,948...52,116,018
Ensembl chr17:51,948,948...52,115,214

G

zinc finger E-box binding homeobox 2

multiple interactions

[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of ZEB2 mRNA

NCBI chr 3:29,214,581...29,344,890
Ensembl chr 3:29,218,301...29,345,157

cyclohexanone

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

glutamate dehydrogenase 1

multiple interactions

cyclohexanone promotes the reaction [2-dichlorobenzene results in increased activity of GLUD1 protein]

NCBI chr16:9,640,312...9,673,961
Ensembl chr16:9,640,312...9,673,957

G

progesterone receptor

multiple interactions

cyclohexanone binds to and results in decreased activity of PGR protein

NCBI chr 8:6,072,673...6,131,552
Ensembl chr 8:6,072,673...6,131,344

cyclohexanones

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

olfactory receptor family 5 subfamily D member 18

multiple interactions

Cyclohexanones binds to and results in increased activity of OR5D18 protein

NCBI chr 3:73,516,522...73,517,463
Ensembl chr 3:73,516,364...73,519,858
Ensembl chr 3:73,516,364...73,519,858

cyclopentanone

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

aldo-keto reductase family 1, member C1

increases reduction
multiple interactions

AKR1C1 protein results in increased reduction of cyclopentanone
NADP promotes the reaction [AKR1C1 protein results in increased reduction of cyclopentanone]

NCBI chr17:65,810,474...65,837,385
Ensembl chr17:65,810,475...65,837,326

G

aldo-keto reductase family 1, member C2

multiple interactions
increases reduction

[AKR1C2 protein co-treated with NADP] results in increased reduction of cyclopentanone; NADP promotes the reaction [AKR1C2 protein results in increased reduction of cyclopentanone]; Ursodeoxycholic Acid inhibits the reaction [[AKR1C2 protein co-treated with NADP] results in increased reduction of cyclopentanone]

NCBI chr17:65,759,778...65,808,013
Ensembl chr17:65,759,788...65,775,764

G

aldo-keto reductase family 1, member C3

multiple interactions
increases reduction

[AKR1C3 protein co-treated with NADP] results in increased reduction of cyclopentanone; Medroxyprogesterone Acetate inhibits the reaction [[AKR1C3 protein co-treated with NADP] results in increased reduction of cyclopentanone]; NADP promotes the reaction [AKR1C3 protein results in increased reduction of cyclopentanone]

NCBI chr17:66,110,970...66,127,867
Ensembl chr17:66,110,963...66,127,873

diphenylcyclopropenone

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

adrenomedullin

increases expression

diphenylcyclopropenone results in increased expression of ADM mRNA

NCBI chr 1:164,745,484...164,747,655
Ensembl chr 1:164,745,466...164,747,654

G

ankyrin repeat domain 37

increases expression

diphenylcyclopropenone results in increased expression of ANKRD37 mRNA

NCBI chr16:46,268,933...46,271,971
Ensembl chr16:46,268,443...46,271,963

G

cyclin-dependent kinase 12

decreases expression

diphenylcyclopropenone results in decreased expression of CDK12 mRNA

NCBI chr10:83,201,177...83,256,906
Ensembl chr10:83,201,211...83,280,888
Ensembl chr10:83,201,211...83,280,888

G

DNA methyltransferase 3 beta

decreases expression

diphenylcyclopropenone results in decreased expression of DNMT3B mRNA

NCBI chr 3:142,130,588...142,169,128
Ensembl chr 3:142,130,592...142,169,124

G

Fos proto-oncogene, AP-1 transcription factor subunit

increases expression

diphenylcyclopropenone results in increased expression of FOS mRNA

NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036

G

FOS like 1, AP-1 transcription factor subunit

increases expression

diphenylcyclopropenone results in increased expression of FOSL1 mRNA

NCBI chr 1:202,754,549...202,763,057
Ensembl chr 1:202,754,529...202,764,930

G

heme oxygenase 1

increases expression

diphenylcyclopropenone results in increased expression of HMOX1 mRNA

PMID:20491607 PMID:25236440

NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079

G

MAF bZIP transcription factor F

increases expression

diphenylcyclopropenone results in increased expression of MAFF mRNA

NCBI chr 7:110,912,367...110,923,711
Ensembl chr 7:110,912,499...110,923,851

G

metallothionein 1

increases expression

diphenylcyclopropenone results in increased expression of MT1A mRNA

NCBI chr19:10,826,032...10,827,048
Ensembl chr19:10,826,032...10,827,049
Ensembl chr17:10,826,032...10,827,049
Ensembl chr X:10,826,032...10,827,049

G

metallothionein 2A

increases expression

diphenylcyclopropenone results in increased expression of MT2A mRNA

NCBI chr19:10,832,009...10,832,783
Ensembl chr19:10,832,002...10,832,784

G

RNA binding motif protein 5

decreases expression

diphenylcyclopropenone results in decreased expression of RBM5 mRNA

NCBI chr 8:108,420,220...108,449,481
Ensembl chr 8:108,420,222...108,449,430

G

sulfiredoxin 1

increases expression

diphenylcyclopropenone results in increased expression of SRXN1 mRNA

NCBI chr 3:140,604,490...140,610,050
Ensembl chr 3:140,599,608...140,628,448

G

stanniocalcin 2

decreases expression

diphenylcyclopropenone results in decreased expression of STC2 mRNA

NCBI chr10:16,251,046...16,260,815
Ensembl chr10:16,250,853...16,262,973

G

thioredoxin 1

increases expression

diphenylcyclopropenone results in increased expression of TXN mRNA

NCBI chr 5:72,712,334...72,724,564
Ensembl chr 5:72,711,933...72,724,629

esketamine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

angiopoietin-like 4

increases expression

Esketamine results in increased expression of ANGPTL4 mRNA

NCBI chr 7:14,550,288...14,557,797
Ensembl chr 7:14,550,311...14,556,519

G

ankyrin repeat domain 1

decreases expression

Esketamine results in decreased expression of ANKRD1 mRNA

NCBI chr 1:233,815,851...233,834,891
Ensembl chr 1:233,815,851...233,834,919

G

ankyrin repeat domain 2

decreases expression

Esketamine results in decreased expression of ANKRD2 mRNA

NCBI chr 1:240,847,111...240,856,563
Ensembl chr 1:240,847,072...240,856,566

G

aryl hydrocarbon receptor nuclear translocator 2

increases expression

Esketamine results in increased expression of ARNT2 mRNA

NCBI chr 1:138,236,235...138,392,868
Ensembl chr 1:138,189,940...138,393,153

G

arrestin domain containing 4

decreases expression

Esketamine results in decreased expression of ARRDC4 mRNA

NCBI chr 1:122,369,355...122,383,351
Ensembl chr 1:122,369,360...122,383,290

G

activating transcription factor 4

increases expression
multiple interactions

Esketamine results in increased expression of ATF4 mRNA; Esketamine results in increased expression of ATF4 protein
N-Methylaspartate results in decreased expression of [Esketamine results in increased expression of ATF4 protein]

NCBI chr 7:111,804,135...111,806,457
Ensembl chr 7:111,804,183...111,806,446

G

activating transcription factor 6

increases expression

Esketamine results in increased expression of ATF6 mRNA

NCBI chr13:82,927,579...83,106,381
Ensembl chr13:82,930,034...83,107,177

G

beta-1,3-galactosyltransferase 9

decreases expression

Esketamine results in decreased expression of B3GALT9 mRNA

NCBI chr 3:18,121,620...18,124,149
Ensembl chr 3:18,101,407...18,123,894
Ensembl chr 3:18,101,407...18,123,894

G

BCL2 associated X, apoptosis regulator

affects expression
multiple interactions
increases expression

Esketamine affects the expression of BAX mRNA
EIF2AK3 protein affects the reaction [Esketamine affects the expression of BAX mRNA]; N-Methylaspartate affects the reaction [Esketamine affects the expression of BAX mRNA]
Esketamine results in increased expression of BAX protein

NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368

G

BCL2, apoptosis regulator

decreases expression
multiple interactions
affects expression

Esketamine results in decreased expression of BCL2 protein
EIF2AK3 protein affects the reaction [Esketamine affects the expression of BCL2 mRNA]; N-Methylaspartate affects the reaction [Esketamine affects the expression of BCL2 mRNA]

NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

caspase 3

increases cleavage

Esketamine results in increased cleavage of CASP3 protein

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

cystatin A

increases expression

Esketamine results in increased expression of CSTA mRNA

NCBI chr11:64,620,483...64,631,488
Ensembl chr11:64,620,483...64,631,488

G

DNA-damage inducible transcript 3

increases expression
multiple interactions

Esketamine results in increased expression of DDIT3 mRNA; Esketamine results in increased expression of DDIT3 protein
EIF2AK3 protein affects the reaction [Esketamine results in increased expression of DDIT3 mRNA]; N-Methylaspartate results in decreased expression of [Esketamine results in increased expression of DDIT3 protein]

NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201

G

dynein light chain Tctex-type 2B

decreases expression

Esketamine results in decreased expression of DYNLT2B mRNA

NCBI chr11:68,359,138...68,367,573
Ensembl chr11:68,358,263...68,367,499

G

eukaryotic translation initiation factor 2 alpha kinase 3

multiple interactions
increases phosphorylation
increases expression

EIF2AK3 protein affects the reaction [Esketamine affects the expression of BAX mRNA]; EIF2AK3 protein affects the reaction [Esketamine affects the expression of BCL2 mRNA]; EIF2AK3 protein affects the reaction [Esketamine results in increased expression of DDIT3 mRNA]
Esketamine results in increased phosphorylation of EIF2AK3 protein
Esketamine results in increased expression of EIF2AK3 mRNA

NCBI chr 4:102,805,495...102,866,914
Ensembl chr 4:102,805,510...102,866,911

G

family with sequence similarity 227, member B

decreases expression

Esketamine results in decreased expression of FAM227B mRNA

NCBI chr 3:113,226,662...113,392,396
Ensembl chr 3:113,233,205...113,392,320

G

GATA binding protein 3

decreases expression

Esketamine results in decreased expression of GATA3 mRNA

NCBI chr17:68,643,760...68,666,000
Ensembl chr17:68,643,873...68,665,391

G

growth differentiation factor 15

increases expression

Esketamine results in increased expression of GDF15 mRNA

NCBI chr16:18,804,457...18,808,043
Ensembl chr16:18,805,239...18,808,055

G

G protein-coupled receptor 17

increases expression

Esketamine results in increased expression of GPR17 mRNA

NCBI chr18:23,576,232...23,583,153
Ensembl chr18:23,577,242...23,582,966

G

interferon induced transmembrane protein 10

increases expression

Esketamine results in increased expression of IFITM10 mRNA

NCBI chr 1:197,507,501...197,524,180
Ensembl chr 1:197,507,503...197,525,151

G

immunoglobulin superfamily, member 9B

increases expression

Esketamine results in increased expression of IGSF9B mRNA

NCBI chr 8:25,712,644...25,769,481
Ensembl chr 8:25,712,644...25,758,554

G

interleukin 12A

decreases expression

Esketamine results in decreased expression of IL12A mRNA

NCBI chr 2:152,965,769...152,973,035
Ensembl chr 2:152,965,769...152,972,734

G

killer cell lectin like receptor G1

decreases expression

Esketamine results in decreased expression of KLRG1 mRNA

NCBI chr 4:155,455,465...155,467,301
Ensembl chr 4:155,455,495...155,467,424

G

lysosomal protein transmembrane 5

increases expression

Esketamine results in increased expression of LAPTM5 mRNA

NCBI chr 5:143,087,759...143,109,807
Ensembl chr 5:143,087,759...143,109,807

G

MAF bZIP transcription factor B

increases expression

Esketamine results in increased expression of MAFB mRNA

NCBI chr 3:148,998,111...149,000,031
Ensembl chr 3:148,998,122...149,000,031

G

membrane associated ring-CH-type finger 4

decreases expression

Esketamine results in decreased expression of MARCHF4 mRNA

NCBI chr 9:74,078,437...74,196,070
Ensembl chr 9:74,078,434...74,198,199

G

MAM domain containing glycosylphosphatidylinositol anchor 1

increases expression

Esketamine results in increased expression of MDGA1 mRNA

NCBI chr20:7,900,327...7,964,309
Ensembl chr20:7,904,358...7,963,471

G

netrin G2

increases expression

Esketamine results in increased expression of NTNG2 mRNA

NCBI chr 3:12,492,574...12,551,104
Ensembl chr 3:12,492,639...12,545,890

G

phosphodiesterase 2A

increases expression

Esketamine results in increased expression of PDE2A mRNA

NCBI chr 1:155,823,590...155,915,434
Ensembl chr 1:155,813,180...155,915,434

G

PTPRF interacting protein alpha 4

increases expression

Esketamine results in increased expression of PPFIA4 mRNA

NCBI chr13:45,753,827...45,802,305
Ensembl chr13:45,753,827...45,802,261

G

PRELI domain containing 3A

decreases expression

Esketamine results in decreased expression of PRELID3A mRNA

NCBI chr18:60,998,898...61,034,821
Ensembl chr18:61,017,764...61,031,883

G

pyrroline-5-carboxylate reductase 3

decreases expression

Esketamine results in decreased expression of PYCR3 mRNA

NCBI chr 7:107,603,543...107,608,831
Ensembl chr 7:107,581,930...107,608,799

G

reelin

decreases expression

Esketamine results in decreased expression of RELN mRNA

NCBI chr 4:12,736,177...13,162,956
Ensembl chr 4:12,736,130...13,162,211

G

regulator of G-protein signaling 5

decreases expression

Esketamine results in decreased expression of RGS5 mRNA

NCBI chr13:81,848,254...81,885,053
Ensembl chr13:81,836,304...81,885,518

G

reactive intermediate imine deaminase A homolog

decreases expression

Esketamine results in decreased expression of RIDA mRNA

NCBI chr 7:65,691,429...65,705,257
Ensembl chr 7:65,691,435...65,705,716

G

RAR-related orphan receptor A

increases expression

Esketamine results in increased expression of RORA mRNA

NCBI chr 8:69,301,635...70,034,741
Ensembl chr 8:69,301,733...70,025,931

G

spalt-like transcription factor 4

decreases expression

Esketamine results in decreased expression of SALL4 mRNA

NCBI chr 3:157,474,067...157,491,055
Ensembl chr 3:157,474,642...157,490,822

G

semaphorin 5A

decreases expression

Esketamine results in decreased expression of SEMA5A mRNA

NCBI chr 2:83,309,843...83,741,084
Ensembl chr 2:83,309,843...83,741,084

G

solute carrier family 6 member 12

increases expression

Esketamine results in increased expression of SLC6A12 mRNA

NCBI chr 4:154,585,386...154,603,750
Ensembl chr 4:154,585,500...154,603,750

G

solute carrier organic anion transporter family, member 2a1

decreases expression

Esketamine results in decreased expression of SLCO2A1 mRNA

NCBI chr 8:103,588,916...103,672,546
Ensembl chr 8:103,588,916...103,672,546

G

SLIT and NTRK-like family, member 6

increases expression

Esketamine results in increased expression of SLITRK6 mRNA

NCBI chr15:87,563,506...87,570,125
Ensembl chr15:87,563,322...87,570,393

G

secreted phosphoprotein 1

increases expression

Esketamine results in increased expression of SPP1 mRNA

NCBI chr14:5,308,885...5,315,120
Ensembl chr14:5,308,885...5,315,162

G

synaptonemal complex protein 2

increases expression

Esketamine results in increased expression of SYCP2 mRNA

NCBI chr 3:165,431,715...165,502,134
Ensembl chr 3:165,436,331...165,498,789

G

troponin C1, slow skeletal and cardiac type

decreases expression

Esketamine results in decreased expression of TNNC1 mRNA

NCBI chr16:6,400,801...6,405,634
Ensembl chr16:6,402,171...6,405,634

G

transient receptor potential cation channel, subfamily V, member 3

increases expression

Esketamine results in increased expression of TRPV3 mRNA

NCBI chr10:57,883,546...57,915,865
Ensembl chr10:57,883,546...57,913,296

G

unc-13 homolog A

increases expression

Esketamine results in increased expression of UNC13A mRNA

NCBI chr16:18,333,910...18,381,813
Ensembl chr16:18,336,229...18,381,872

G

von Willebrand factor A domain containing 5A

increases expression

Esketamine results in increased expression of VWA5A mRNA

NCBI chr 8:38,815,176...38,848,674
Ensembl chr 8:38,815,210...38,839,112

G

X-box binding protein 1

increases expression

Esketamine results in increased expression of XBP1 mRNA

NCBI chr14:80,390,629...80,395,713
Ensembl chr14:80,390,643...80,395,693

G

zinc finger protein 239

decreases expression

Esketamine results in decreased expression of ZNF239 mRNA

NCBI chr 4:151,029,431...151,039,283
Ensembl chr 4:151,029,405...151,039,529

fenchone

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

nuclear receptor subfamily 3, group C, member 1

multiple interactions

fenchone binds to and results in decreased activity of NR3C1 protein

NCBI chr18:31,271,681...31,393,320
Ensembl chr18:31,271,681...31,393,375

G

peroxisome proliferator-activated receptor gamma

multiple interactions

fenchone binds to and results in decreased activity of PPARG protein

NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468

friedelin

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

caspase 3

multiple interactions

friedelin inhibits the reaction [Ethanol results in increased expression of CASP3 protein]

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

poly (ADP-ribose) polymerase 1

multiple interactions

friedelin inhibits the reaction [Ethanol results in increased expression of PARP1 protein]

NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404

G

RELA proto-oncogene, NF-kB subunit

multiple interactions

friedelin inhibits the reaction [Ethanol results in increased expression of RELA protein]

NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484

glycyrrhetinic acid

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily B member 11

multiple interactions

18alpha-glycyrrhetinic acid inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of ABCB11 mRNA]

NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730

G

ATP binding cassette subfamily B member 1A

multiple interactions

18alpha-glycyrrhetinic acid inhibits the reaction [ABCB1 protein results in increased transport of Digoxin]; [Glycyrrhetinic Acid affects the activity of ABCB1 protein] which affects the susceptibility to Vinblastine; [Glycyrrhetinic Acid affects the activity of ABCB1 protein] which results in increased abundance of Daunorubicin; Glycyrrhetinic Acid inhibits the reaction [ABCB1 protein results in increased uptake of Digoxin]; Glycyrrhetinic Acid inhibits the reaction [Verapamil results in increased activity of ABCB1 protein]

PMID:16904803 PMID:18204840 PMID:24380838

NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709

G

ATP binding cassette subfamily B member 4

multiple interactions

18alpha-glycyrrhetinic acid inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of ABCB4 mRNA]

NCBI chr 4:25,150,998...25,209,489
Ensembl chr 4:25,151,953...25,209,202

G

ATP binding cassette subfamily C member 1

multiple interactions
increases activity

18alpha-glycyrrhetinic acid inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of ABCC1 mRNA]
Glycyrrhetinic Acid results in increased activity of ABCC1 protein
[Glycyrrhetinic Acid affects the activity of ABCC1 protein] which affects the susceptibility to Doxorubicin; [Glycyrrhetinic Acid affects the activity of ABCC1 protein] which results in increased abundance of fluorexon

PMID:18204840 PMID:28549656

NCBI chr10:528,961...655,179
Ensembl chr10:531,812...655,114

G

ATP binding cassette subfamily C member 2

multiple interactions

Glycyrrhetinic Acid inhibits the reaction [ABCC2 protein results in increased transport of estradiol-17 beta-glucuronide]

NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238

G

ATP binding cassette subfamily C member 3

multiple interactions

18alpha-glycyrrhetinic acid affects the reaction [1-Naphthylisothiocyanate affects the expression of ABCC3 mRNA]

NCBI chr10:79,296,681...79,342,749
Ensembl chr10:79,296,693...79,342,595

G

ATP binding cassette subfamily G member 2

multiple interactions

Glycyrrhetinic Acid inhibits the reaction [ABCG2 protein results in increased transport of estradiol-17 beta-glucuronide]

NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409

G

ATP binding cassette subfamily G member 5

multiple interactions

18alpha-glycyrrhetinic acid inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of ABCG5 mRNA]

NCBI chr 6:9,965,118...9,990,563
Ensembl chr 6:9,965,118...9,990,563

G

acetyl-CoA acetyltransferase 2

multiple interactions

18alpha-glycyrrhetinic acid affects the reaction [1-Naphthylisothiocyanate affects the expression of ACAT2 mRNA]

NCBI chr 1:47,695,833...47,713,879
Ensembl chr 1:47,695,788...47,752,821

G

actin alpha 2, smooth muscle

multiple interactions

18alpha-glycyrrhetinic acid inhibits the reaction [Monocrotaline results in increased expression of ACTA2 protein]

NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554

G

aldo-keto reductase family 1, member C1

decreases activity

Glycyrrhetinic Acid results in decreased activity of AKR1C1 protein

NCBI chr17:65,810,474...65,837,385
Ensembl chr17:65,810,475...65,837,326

G

aldo-keto reductase family 1, member C2

decreases activity

Glycyrrhetinic Acid results in decreased activity of AKR1C2 protein

NCBI chr17:65,759,778...65,808,013
Ensembl chr17:65,759,788...65,775,764

G

aldo-keto reductase family 1, member C3

affects activity
decreases activity

18alpha-glycyrrhetinic acid affects the activity of AKR1C3 protein
Glycyrrhetinic Acid results in decreased activity of AKR1C3 protein

PMID:11165023 PMID:12604236

NCBI chr17:66,110,970...66,127,867
Ensembl chr17:66,110,963...66,127,873

G

albumin

multiple interactions

ALB protein binds to and affects the transport of Glycyrrhetinic Acid

NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836

G

alkaline phosphatase, biomineralization associated

multiple interactions

18alpha-glycyrrhetinic acid inhibits the reaction [BMP2 protein results in increased activity of ALPL protein]; 18alpha-glycyrrhetinic acid inhibits the reaction [BMP2 protein results in increased expression of ALPL mRNA]; 18alpha-glycyrrhetinic acid inhibits the reaction [Ethinyl Estradiol results in increased expression of ALPL protein]; 18alpha-glycyrrhetinic acid inhibits the reaction [RUNX2 protein results in increased expression of ALPL mRNA]

PMID:21910061 PMID:38244730

NCBI chr 5:149,951,397...150,006,424
Ensembl chr 5:149,951,409...150,006,446

G

activating transcription factor 6

multiple interactions

18alpha-glycyrrhetinic acid inhibits the reaction [bisphenol A results in increased expression of ATF6 mRNA]

NCBI chr13:82,927,579...83,106,381
Ensembl chr13:82,930,034...83,107,177

G

ATPase phospholipid transporting 8B1

multiple interactions

18alpha-glycyrrhetinic acid inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of ATP8B1 mRNA]

NCBI chr18:58,016,382...58,157,213
Ensembl chr18:58,018,268...58,157,396

G

BCL2 associated X, apoptosis regulator

multiple interactions
decreases expression

18alpha-glycyrrhetinic acid inhibits the reaction [bisphenol A results in increased expression of BAX]; 18alpha-glycyrrhetinic acid inhibits the reaction [Methotrexate results in increased expression of BAX protein]; Glycyrrhetinic Acid promotes the reaction [bisphenol A results in increased expression of BAX protein]
Glycyrrhetinic Acid results in decreased expression of BAX protein
18alpha-glycyrrhetinic acid inhibits the reaction [[PDGFB protein co-treated with PDGFB protein] results in decreased expression of BAX protein]

PMID:28414158 PMID:31325423 PMID:35699857 PMID:38348715

NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368

G

BCL2, apoptosis regulator

multiple interactions
decreases expression

18alpha-glycyrrhetinic acid inhibits the reaction [bisphenol A results in decreased expression of BCL2]; 18alpha-glycyrrhetinic acid inhibits the reaction [Methotrexate results in decreased expression of BCL2 protein]; Glycyrrhetinic Acid inhibits the reaction [bisphenol A results in decreased expression of BCL2 protein]
Glycyrrhetinic Acid results in decreased expression of BCL2 protein
18alpha-glycyrrhetinic acid inhibits the reaction [[PDGFB protein co-treated with PDGFB protein] results in increased expression of BCL2 protein]

PMID:28414158 PMID:31325423 PMID:35699857 PMID:38348715

NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

bone gamma-carboxyglutamate protein

multiple interactions

18alpha-glycyrrhetinic acid inhibits the reaction [BMP2 protein results in increased activity of BGLAP protein]; 18alpha-glycyrrhetinic acid inhibits the reaction [BMP2 protein results in increased expression of BGLAP mRNA]; 18alpha-glycyrrhetinic acid inhibits the reaction [RUNX2 protein results in increased expression of BGLAP mRNA]

NCBI chr 2:173,838,518...173,839,495
Ensembl chr 2:173,838,518...173,839,495

G

bone morphogenetic protein 2

multiple interactions

18alpha-glycyrrhetinic acid inhibits the reaction [BMP2 protein results in increased activity of ALPL protein]; 18alpha-glycyrrhetinic acid inhibits the reaction [BMP2 protein results in increased activity of BGLAP protein]; 18alpha-glycyrrhetinic acid inhibits the reaction [BMP2 protein results in increased activity of RUNX2 protein]; 18alpha-glycyrrhetinic acid inhibits the reaction [BMP2 protein results in increased expression of ALPL mRNA]; 18alpha-glycyrrhetinic acid inhibits the reaction [BMP2 protein results in increased expression of BGLAP mRNA]; 18alpha-glycyrrhetinic acid inhibits the reaction [BMP2 protein results in increased expression of COL1A1 mRNA]; 18alpha-glycyrrhetinic acid inhibits the reaction [BMP2 protein results in increased expression of SP7 mRNA]

NCBI chr 3:120,812,660...120,822,579
Ensembl chr 3:120,812,882...120,821,397

G

caspase 3

multiple interactions

18alpha-glycyrrhetinic acid inhibits the reaction [bisphenol A results in increased expression of CASP3]

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

catalase

multiple interactions

Glycyrrhetinic Acid inhibits the reaction [Carbon Tetrachloride results in decreased expression of CAT mRNA]
Glycyrrhetinic Acid inhibits the reaction [bisphenol A results in decreased activity of CAT protein]

PMID:23341968 PMID:38348715

NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478

G

cyclin-dependent kinase inhibitor 1B

multiple interactions

18alpha-glycyrrhetinic acid inhibits the reaction [[PDGFB protein co-treated with PDGFB protein] results in decreased expression of CDKN1B protein]

NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982

G

collagen type I alpha 1 chain

multiple interactions

18alpha-glycyrrhetinic acid inhibits the reaction [BMP2 protein results in increased expression of COL1A1 mRNA]

NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624

G

colony stimulating factor 2

multiple interactions

Glycyrrhetinic Acid promotes the reaction [Hydrocortisone inhibits the reaction [IL1B protein results in increased secretion of CSF2 protein]]

NCBI chr10:38,386,945...38,388,926
Ensembl chr10:38,386,945...38,389,199

G

C-X-C motif chemokine receptor 3

multiple interactions

18alpha-glycyrrhetinic acid inhibits the reaction [Ethinyl Estradiol results in increased expression of CXCR3 mRNA]

NCBI chr X:66,844,318...66,846,969
Ensembl chr X:66,844,318...66,846,969

G

cytochrome c, somatic

multiple interactions
decreases expression

Glycyrrhetinic Acid inhibits the reaction [bisphenol A results in increased expression of CYCS protein]
Glycyrrhetinic Acid results in decreased expression of CYCS protein

NCBI chr 4:79,651,894...79,653,994
Ensembl chr 4:79,651,378...79,654,054
Ensembl chr18:79,651,378...79,654,054

G

cytochrome P450, family 1, subfamily a, polypeptide 2

multiple interactions

[brucine co-treated with Glycyrrhetinic Acid] results in decreased activity of CYP1A2 protein

NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312

G

cytochrome P450, family 2, subfamily e, polypeptide 1

multiple interactions

[brucine co-treated with Glycyrrhetinic Acid] results in decreased activity of CYP2E1 protein

NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023

G

cytochrome P450 family 7 subfamily A member 1

multiple interactions

18alpha-glycyrrhetinic acid inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of CYP7A1 mRNA]

NCBI chr 5:19,376,979...19,386,676
Ensembl chr 5:19,376,974...19,386,688

G

eukaryotic translation initiation factor 2 alpha kinase 3

multiple interactions

18alpha-glycyrrhetinic acid inhibits the reaction [bisphenol A results in increased expression of EIF2AK3 mRNA]

NCBI chr 4:102,805,495...102,866,914
Ensembl chr 4:102,805,510...102,866,911

G

endoplasmic reticulum to nucleus signaling 1

multiple interactions

18alpha-glycyrrhetinic acid inhibits the reaction [Cadmium Chloride results in increased expression of ERN1 protein]
18alpha-glycyrrhetinic acid inhibits the reaction [bisphenol A results in increased expression of ERN1 mRNA]

PMID:29444456 PMID:35699857

NCBI chr10:91,326,889...91,421,201
Ensembl chr10:91,330,654...91,421,029

G

gamma-glutamyltransferase 1

multiple interactions

18alpha-glycyrrhetinic acid inhibits the reaction [Methotrexate results in increased activity of GGT1 protein]

NCBI chr20:13,074,695...13,104,095
Ensembl chr20:13,074,700...13,108,442

G

glutamic-oxaloacetic transaminase 1

multiple interactions

18alpha-glycyrrhetinic acid inhibits the reaction [Ethinyl Estradiol results in increased expression of GOT1 protein]

NCBI chr 1:242,357,293...242,381,535
Ensembl chr 1:242,357,306...242,380,633

G

glutamic--pyruvic transaminase

multiple interactions

18alpha-glycyrrhetinic acid inhibits the reaction [Methotrexate results in increased activity of GPT protein]
18alpha-glycyrrhetinic acid inhibits the reaction [1-Naphthylisothiocyanate results in increased activity of GPT protein]; 18alpha-glycyrrhetinic acid inhibits the reaction [Ethinyl Estradiol results in increased expression of GPT protein]; Glycyrrhetinic Acid inhibits the reaction [diosbulbin B results in increased activity of GPT protein]

PMID:28414158 PMID:28549656 PMID:36807597 PMID:38244730

NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494

G

glutathione peroxidase 2

multiple interactions

Glycyrrhetinic Acid inhibits the reaction [Carbon Tetrachloride results in decreased expression of GPX2 mRNA]

NCBI chr 6:95,493,589...95,496,877
Ensembl chr 6:95,493,589...95,496,877

G

heme oxygenase 1

multiple interactions

18alpha-glycyrrhetinic acid inhibits the reaction [Methotrexate results in decreased expression of HMOX1 mRNA]

NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079

G

HRas proto-oncogene, GTPase

decreases expression

Glycyrrhetinic Acid results in decreased expression of HRAS protein

NCBI chr 1:196,290,127...196,299,823
Ensembl chr 1:196,296,263...196,300,615

G

hydroxysteroid 11-beta dehydrogenase 1

decreases activity

18alpha-glycyrrhetinic acid results in decreased activity of HSD11B1 protein

NCBI chr13:104,728,539...104,798,884
Ensembl chr13:104,728,539...104,788,687

G

hydroxysteroid 11-beta dehydrogenase 2

decreases activity
multiple interactions

18alpha-glycyrrhetinic acid results in decreased activity of HSD11B2 protein
Glycyrrhetinic Acid inhibits the reaction [tributyltin results in increased activity of HSD11B2 protein]; Glycyrrhetinic Acid inhibits the reaction [triphenyltin chloride results in increased activity of HSD11B2 protein]

PMID:24135201 PMID:31927052

NCBI chr19:33,397,656...33,402,899
Ensembl chr19:33,397,656...33,402,899

G

hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1

multiple interactions

[Glycyrrhetinic Acid co-treated with NADP] binds to HSD3B1 protein

NCBI chr 2:186,169,864...186,175,984
Ensembl chr 2:186,169,863...186,175,999

G

heat shock protein family A (Hsp70) member 5

multiple interactions

18alpha-glycyrrhetinic acid inhibits the reaction [bisphenol A results in increased expression of HSPA5 mRNA]

NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891

G

interleukin 1 beta

multiple interactions

Glycyrrhetinic Acid promotes the reaction [Hydrocortisone inhibits the reaction [IL1B protein results in increased secretion of CSF2 protein]]
Glycyrrhetinic Acid inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of IL1B mRNA]
18alpha-glycyrrhetinic acid inhibits the reaction [Methotrexate results in increased expression of IL1B protein]

PMID:10460758 PMID:23373965 PMID:28414158

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

interleukin 6

multiple interactions

18alpha-glycyrrhetinic acid inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of IL6 protein]; 18alpha-glycyrrhetinic acid inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 protein]; Glycyrrhetinic Acid inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of IL6 mRNA]

PMID:21644799 PMID:23373965 PMID:24849676

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

interleukin-1 receptor-associated kinase 1

multiple interactions

Glycyrrhetinic Acid inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] promotes the reaction [TRAF6 protein binds to IRAK1 protein]]

NCBI chr X:151,768,621...151,778,521
Ensembl chr X:151,768,777...151,778,521

G

interleukin-1 receptor-associated kinase 3

multiple interactions
increases expression

[Glycyrrhetinic Acid co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased expression of IRAK3 mRNA; IRAK3 protein promotes the reaction [Glycyrrhetinic Acid inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of TNF protein]]
Glycyrrhetinic Acid results in increased expression of IRAK3 protein

NCBI chr 7:55,653,949...55,714,371
Ensembl chr 7:55,653,962...55,713,121

G

lymphocyte antigen 96

multiple interactions

Glycyrrhetinic Acid inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of [TLR4 protein binds to LY96 protein]]

NCBI chr 5:2,582,233...2,612,357
Ensembl chr 5:2,582,254...2,612,386

G

mitogen-activated protein kinase kinase kinase 5

multiple interactions

18alpha-glycyrrhetinic acid inhibits the reaction [Cadmium Chloride results in increased expression of MAP3K5 protein]

NCBI chr 1:14,685,776...14,904,935
Ensembl chr 1:14,685,492...14,904,800

G

mitogen activated protein kinase 1

multiple interactions

Glycyrrhetinic Acid inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased phosphorylation of MAPK1 protein]

NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616

G

mitogen activated protein kinase 3

multiple interactions

Glycyrrhetinic Acid inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased phosphorylation of MAPK3 protein]

NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863

G

matrix metallopeptidase 9

multiple interactions

18alpha-glycyrrhetinic acid inhibits the reaction [TNF protein results in increased activity of MMP9 protein]; 18alpha-glycyrrhetinic acid inhibits the reaction [TNF protein results in increased expression of MMP9 mRNA]

NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120

G

myeloperoxidase

multiple interactions

Glycyrrhetinic Acid inhibits the reaction [diosbulbin B results in increased activity of MPO protein]

NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819

G

microsomal triglyceride transfer protein

multiple interactions

18alpha-glycyrrhetinic acid inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of MTTP mRNA]

NCBI chr 2:226,613,090...226,654,239
Ensembl chr 2:226,613,090...226,654,239

G

NFE2 like bZIP transcription factor 2

multiple interactions
increases expression

[Glycyrrhetinic Acid results in increased expression of NFE2L2] which results in decreased susceptibility to Carbon Tetrachloride; Glycyrrhetinic Acid inhibits the reaction [Carbon Tetrachloride affects the localization of NFE2L2 protein]
18alpha-glycyrrhetinic acid inhibits the reaction [Methotrexate results in decreased expression of NFE2L2 mRNA]; 18alpha-glycyrrhetinic acid inhibits the reaction [Methotrexate results in decreased expression of NFE2L2 protein]

PMID:23341968 PMID:28414158

NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737

G

nuclear factor kappa B subunit 1

multiple interactions

18alpha-glycyrrhetinic acid inhibits the reaction [TNF protein results in decreased expression of NFKB1 protein]

NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404

G

NFKB inhibitor alpha

multiple interactions

18alpha-glycyrrhetinic acid inhibits the reaction [TNF protein results in increased phosphorylation of and results in increased degradation of NFKBIA protein]
Glycyrrhetinic Acid inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased phosphorylation of NFKBIA protein]; Glycyrrhetinic Acid inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased phosphorylation of and affects the localization of NFKBIA protein]

PMID:23373965 PMID:24613819 PMID:28213090

NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941

G

nitric oxide synthase 2

multiple interactions

18alpha-glycyrrhetinic acid inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of NOS2 mRNA]; 18alpha-glycyrrhetinic acid inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of NOS2 protein]; Glycyrrhetinic Acid inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of NOS2 protein]

PMID:21644799 PMID:23373965

NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210

G

NPC1 like intracellular cholesterol transporter 1

multiple interactions

18alpha-glycyrrhetinic acid inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of NPC1L1 mRNA]

NCBI chr14:81,071,448...81,091,113
Ensembl chr14:81,071,451...81,091,113

G

nuclear receptor subfamily 1, group H, member 4

multiple interactions

glycyrrhetinic acid inhibits the reaction [1-naphthyl isothiocyanate decreases expression of Nr1h4 mRNA in liver]

RGD

NCBI chr 7:23,846,122...23,942,085
Ensembl chr 7:23,846,122...23,942,047

G

platelet derived growth factor subunit B

multiple interactions

18alpha-glycyrrhetinic acid inhibits the reaction [[PDGFB protein co-treated with PDGFB protein] results in decreased expression of BAX protein]; 18alpha-glycyrrhetinic acid inhibits the reaction [[PDGFB protein co-treated with PDGFB protein] results in decreased expression of CDKN1B protein]; 18alpha-glycyrrhetinic acid inhibits the reaction [[PDGFB protein co-treated with PDGFB protein] results in increased expression of BCL2 protein]; 18alpha-glycyrrhetinic acid inhibits the reaction [[PDGFB protein co-treated with PDGFB protein] results in increased expression of RHOA mRNA]; 18alpha-glycyrrhetinic acid inhibits the reaction [[PDGFB protein co-treated with PDGFB protein] results in increased expression of RHOA protein]; 18alpha-glycyrrhetinic acid inhibits the reaction [[PDGFB protein co-treated with PDGFB protein] results in increased expression of ROCK1 mRNA]; 18alpha-glycyrrhetinic acid inhibits the reaction [[PDGFB protein co-treated with PDGFB protein] results in increased expression of ROCK1 protein]; 18alpha-glycyrrhetinic acid inhibits the reaction [[PDGFB protein co-treated with PDGFB protein] results in increased expression of ROCK2 mRNA]; 18alpha-glycyrrhetinic acid inhibits the reaction [[PDGFB protein co-treated with PDGFB protein] results in increased expression of ROCK2 protein]; 18alpha-glycyrrhetinic acid inhibits the reaction [[PDGFB protein co-treated with PDGFB protein] results in increased phosphorylation of PPP1R12A protein]

NCBI chr 7:111,539,444...111,557,984
Ensembl chr 7:111,540,345...111,557,984

G

phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit delta

decreases activity

18alpha-glycyrrhetinic acid results in decreased activity of PIK3CD protein

NCBI chr 5:160,094,952...160,142,962
Ensembl chr 5:160,094,952...160,120,930

G

phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit gamma

decreases activity

18alpha-glycyrrhetinic acid results in decreased activity of PIK3CG protein

NCBI chr 6:48,766,778...48,802,098
Ensembl chr 6:48,766,864...48,802,043

G

peroxisome proliferator-activated receptor gamma

multiple interactions

18alpha-glycyrrhetinic acid inhibits the reaction [Methotrexate results in decreased expression of PPARG mRNA]; 18alpha-glycyrrhetinic acid inhibits the reaction [Methotrexate results in decreased expression of PPARG protein]

NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468

G

protein phosphatase 1, regulatory subunit 12A

multiple interactions

18alpha-glycyrrhetinic acid inhibits the reaction [[PDGFB protein co-treated with PDGFB protein] results in increased phosphorylation of PPP1R12A protein]

NCBI chr 7:43,482,808...43,593,689
Ensembl chr 7:43,482,803...43,593,425

G

prostaglandin-endoperoxide synthase 2

multiple interactions

18alpha-glycyrrhetinic acid inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of PTGS2 mRNA]; 18alpha-glycyrrhetinic acid inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of PTGS2 protein]

NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188

G

RELA proto-oncogene, NF-kB subunit

multiple interactions

18alpha-glycyrrhetinic acid inhibits the reaction [TNF protein results in decreased expression of RELA protein]
Glycyrrhetinic Acid inhibits the reaction [lipopolysaccharide, E coli O55-B5 affects the localization of RELA protein]

PMID:23373965 PMID:24613819

NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484

G

renin

decreases activity

Glycyrrhetinic Acid results in decreased activity of REN protein

NCBI chr13:44,796,260...44,807,491
Ensembl chr13:44,796,091...44,807,489

G

ras homolog family member A

multiple interactions

18alpha-glycyrrhetinic acid inhibits the reaction [[PDGFB protein co-treated with PDGFB protein] results in increased expression of RHOA mRNA]; 18alpha-glycyrrhetinic acid inhibits the reaction [[PDGFB protein co-treated with PDGFB protein] results in increased expression of RHOA protein]

NCBI chr 8:108,991,926...109,025,746
Ensembl chr 8:108,991,954...109,025,746

G

Rho-associated coiled-coil containing protein kinase 1

multiple interactions

18alpha-glycyrrhetinic acid inhibits the reaction [[PDGFB protein co-treated with PDGFB protein] results in increased expression of ROCK1 mRNA]; 18alpha-glycyrrhetinic acid inhibits the reaction [[PDGFB protein co-treated with PDGFB protein] results in increased expression of ROCK1 protein]

NCBI chr18:1,114,532...1,236,345
Ensembl chr18:1,115,905...1,235,571

G

Rho-associated coiled-coil containing protein kinase 2

multiple interactions

18alpha-glycyrrhetinic acid inhibits the reaction [[PDGFB protein co-treated with PDGFB protein] results in increased expression of ROCK2 mRNA]; 18alpha-glycyrrhetinic acid inhibits the reaction [[PDGFB protein co-treated with PDGFB protein] results in increased expression of ROCK2 protein]

NCBI chr 6:39,679,116...39,774,033
Ensembl chr 6:39,679,082...39,774,031

G

RAR-related orphan receptor C

multiple interactions

18alpha-glycyrrhetinic acid inhibits the reaction [Ethinyl Estradiol results in increased expression of RORC mRNA]

NCBI chr 2:182,009,707...182,034,910
Ensembl chr 2:182,009,286...182,034,907

G

RUNX family transcription factor 2

multiple interactions

18alpha-glycyrrhetinic acid inhibits the reaction [BMP2 protein results in increased activity of RUNX2 protein]; 18alpha-glycyrrhetinic acid inhibits the reaction [RUNX2 protein results in increased expression of ALPL mRNA]; 18alpha-glycyrrhetinic acid inhibits the reaction [RUNX2 protein results in increased expression of BGLAP mRNA]

NCBI chr 9:16,167,504...16,492,826
Ensembl chr 9:16,167,482...16,492,167

G

SLC51 subunit beta

multiple interactions

18alpha-glycyrrhetinic acid inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of SLC51B mRNA]

NCBI chr 8:65,931,891...65,939,953
Ensembl chr 8:65,931,890...65,940,145

G

solute carrier organic anion transporter family, member 1a4

multiple interactions

18alpha-glycyrrhetinic acid inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of SLCO1A4 mRNA]

NCBI chr 4:174,710,004...174,764,810
Ensembl chr 4:174,710,004...175,254,573

G

superoxide dismutase 3

multiple interactions

Glycyrrhetinic Acid inhibits the reaction [Carbon Tetrachloride results in decreased expression of SOD3 mRNA]

NCBI chr14:58,610,104...58,615,845
Ensembl chr14:58,609,958...58,615,990

G

Sp7 transcription factor

multiple interactions

18alpha-glycyrrhetinic acid inhibits the reaction [BMP2 protein results in increased expression of SP7 mRNA]

NCBI chr 7:133,484,609...133,494,788
Ensembl chr 7:133,484,609...133,494,847

G

toll-like receptor 4

multiple interactions

Glycyrrhetinic Acid inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of [TLR4 protein binds to LY96 protein]]

NCBI chr 5:80,145,867...80,159,501
Ensembl chr 5:80,145,826...80,159,628

G

tumor necrosis factor

multiple interactions

18alpha-glycyrrhetinic acid inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of TNF protein]; Glycyrrhetinic Acid inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased expression of and results in increased secretion of TNF protein]; Glycyrrhetinic Acid inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased expression of TNF mRNA]; Glycyrrhetinic Acid inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of TNF protein]; IRAK3 protein promotes the reaction [Glycyrrhetinic Acid inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of TNF protein]]
18alpha-glycyrrhetinic acid inhibits the reaction [Methotrexate results in increased expression of TNF protein]
18alpha-glycyrrhetinic acid inhibits the reaction [TNF protein results in decreased expression of NFKB1 protein]; 18alpha-glycyrrhetinic acid inhibits the reaction [TNF protein results in decreased expression of RELA protein]; 18alpha-glycyrrhetinic acid inhibits the reaction [TNF protein results in increased activity of MMP9 protein]; 18alpha-glycyrrhetinic acid inhibits the reaction [TNF protein results in increased expression of and results in increased secretion of VEGFA protein]; 18alpha-glycyrrhetinic acid inhibits the reaction [TNF protein results in increased expression of MMP9 mRNA]; 18alpha-glycyrrhetinic acid inhibits the reaction [TNF protein results in increased expression of VEGFA mRNA]; 18alpha-glycyrrhetinic acid inhibits the reaction [TNF protein results in increased phosphorylation of and results in increased degradation of NFKBIA protein]

PMID:21644799 PMID:24613819 PMID:28213090 PMID:28414158

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

G

tumor protein p53

decreases expression

Glycyrrhetinic Acid results in decreased expression of TP53 protein

NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524

G

TNF receptor associated factor 6

multiple interactions

Glycyrrhetinic Acid inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] promotes the reaction [TRAF6 protein binds to IRAK1 protein]]

NCBI chr 3:87,963,517...87,988,316
Ensembl chr 3:87,963,514...87,983,507

G

vascular endothelial growth factor A

multiple interactions

18alpha-glycyrrhetinic acid inhibits the reaction [TNF protein results in increased expression of and results in increased secretion of VEGFA protein]; 18alpha-glycyrrhetinic acid inhibits the reaction [TNF protein results in increased expression of VEGFA mRNA]

NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641

G

X-box binding protein 1

multiple interactions

18alpha-glycyrrhetinic acid inhibits the reaction [Cadmium Chloride results in increased expression of XBP1 protein alternative form]

NCBI chr14:80,390,629...80,395,713
Ensembl chr14:80,390,643...80,395,693

hyperforin

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily B member 1A

increases expression
multiple interactions

hyperforin results in increased expression of ABCB1; hyperforin results in increased expression of ABCB1 mRNA
hyperforin inhibits the reaction [ABCB1 protein results in increased secretion of Ritonavir]

PMID:15266218 PMID:16005588 PMID:24259679

NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709

G

5'-aminolevulinate synthase 1

increases expression

hyperforin results in increased expression of ALAS1 mRNA

NCBI chr 8:106,876,514...106,889,917
Ensembl chr 8:106,876,514...106,889,917

G

BCL2-antagonist/killer 1

increases expression

hyperforin results in increased expression of BAK1 protein

NCBI chr20:5,100,480...5,109,669
Ensembl chr20:5,100,480...5,109,264

G

BCL2 associated X, apoptosis regulator

decreases expression
increases expression
multiple interactions

hyperforin results in decreased expression of BAX mRNA
hyperforin results in increased expression of BAX protein
hyperforin inhibits the reaction [aluminum maltolate results in increased expression of BAX mRNA]

PMID:30481499 PMID:32485087

NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368

G

BCL2, apoptosis regulator

multiple interactions
increases expression

hyperforin inhibits the reaction [aluminum maltolate results in decreased expression of BCL2 mRNA]
hyperforin results in increased expression of BCL2 mRNA

NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

caspase 3

multiple interactions
increases cleavage
decreases expression

hyperforin inhibits the reaction [aluminum maltolate results in increased activity of CASP3 protein]; hyperforin inhibits the reaction [aluminum maltolate results in increased expression of CASP3 mRNA]
hyperforin results in increased cleavage of CASP3 protein
hyperforin results in decreased expression of CASP3 mRNA
hyperforin inhibits the reaction [aluminum maltolate results in increased activity of CASP3 protein]; hyperforin inhibits the reaction [aluminum maltolate results in increased expression of CASP3 mRNA]; hyperforin inhibits the reaction [Propofol results in increased cleavage of CASP3 protein]

PMID:30481499 PMID:32485087 PMID:36640868

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

caspase 8

increases cleavage

hyperforin results in increased cleavage of CASP8 protein

NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542

G

cyclin D1

decreases expression

hyperforin results in decreased expression of CCND1 protein

NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602

G

CASP8 and FADD-like apoptosis regulator

decreases expression

hyperforin results in decreased expression of CFLAR protein

NCBI chr 9:60,185,338...60,236,173
Ensembl chr 9:60,185,452...60,237,034

G

cytochrome c, somatic

multiple interactions
decreases expression

hyperforin inhibits the reaction [aluminum maltolate results in increased expression of CYCS protein]
hyperforin results in decreased expression of CYCS protein

NCBI chr 4:79,651,894...79,653,994
Ensembl chr 4:79,651,378...79,654,054
Ensembl chr18:79,651,378...79,654,054

G

cytochrome P450, family 1, subfamily a, polypeptide 1

multiple interactions
decreases activity

hyperforin inhibits the reaction [CYP1A1 protein affects the metabolism of benzo(a)pyrene 7,8-dihydrodiol]
hyperforin results in decreased activity of CYP1A1 protein

NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125

G

cytochrome P450, family 24, subfamily a, polypeptide 1

increases expression

hyperforin results in increased expression of CYP24A1 mRNA

NCBI chr 3:159,275,947...159,290,383
Ensembl chr 3:159,275,947...159,290,383

G

cytochrome P450, family 2, subfamily b, polypeptide 3

increases expression

hyperforin results in increased expression of CYP2B6 mRNA

NCBI chr 1:81,652,762...81,732,153
Ensembl chr 1:81,652,787...81,732,143

G

cytochrome P450, family 3, subfamily a, polypeptide 2

increases expression
multiple interactions
decreases activity

hyperforin results in increased expression of CYP3A4; hyperforin results in increased expression of CYP3A4 mRNA
hyperforin results in increased expression of and results in increased activity of CYP3A4 protein
hyperforin results in decreased activity of CYP3A4 protein

PMID:15100173 PMID:15266218 PMID:16005588 PMID:16442130 PMID:17954527 More...

NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008

G

cytochrome P450, family 3, subfamily a, polypeptide 9

increases expression

hyperforin results in increased expression of CYP3A5 mRNA

NCBI chr12:16,806,222...16,846,428
Ensembl chr12:16,806,207...16,846,422

G

cytochrome P450 family 7 subfamily A member 1

decreases expression

hyperforin results in decreased expression of CYP7A1 mRNA

NCBI chr 5:19,376,979...19,386,676
Ensembl chr 5:19,376,974...19,386,688

G

epidermal growth factor receptor

decreases phosphorylation

hyperforin results in decreased phosphorylation of EGFR protein

NCBI chr14:91,176,979...91,349,722
Ensembl chr14:91,177,067...91,344,382

G

Fas cell surface death receptor

increases expression

hyperforin results in increased expression of FAS protein

NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591

G

Fas ligand

increases expression

hyperforin results in increased expression of FASLG protein

NCBI chr13:74,151,519...74,172,760
Ensembl chr13:74,154,954...74,162,215

G

intercellular adhesion molecule 1

increases expression

hyperforin results in increased expression of ICAM1 mRNA

NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438

G

Jun proto-oncogene, AP-1 transcription factor subunit

multiple interactions

hyperforin promotes the reaction [JUN protein binds to CXCL8 promoter]

NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656

G

mitogen activated protein kinase 1

increases phosphorylation
decreases phosphorylation

hyperforin results in increased phosphorylation of MAPK1 protein
hyperforin results in decreased phosphorylation of MAPK1 protein

PMID:15622447 PMID:32485087

NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616

G

mitogen activated protein kinase 3

increases phosphorylation
decreases phosphorylation

hyperforin results in increased phosphorylation of MAPK3 protein
hyperforin results in decreased phosphorylation of MAPK3 protein

PMID:15622447 PMID:32485087

NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863

G

MCL1 apoptosis regulator, BCL2 family member

decreases expression

hyperforin results in decreased expression of MCL1 protein

NCBI chr 2:183,219,137...183,235,676
Ensembl chr 2:183,219,220...183,222,303

G

nuclear receptor subfamily 1, group I, member 2

multiple interactions
increases response to substance
affects binding
increases activity

[NR1I2 protein co-treated with hyperforin] results in decreased expression of SLC22A1 mRNA; [NR1I2 protein results in increased susceptibility to hyperforin] which results in decreased expression of SLC22A1 mRNA; hyperforin binds to and results in increased activity of NR1I2 protein; hyperforin promotes the reaction [NR1I2 protein results in decreased expression of SLC22A1 mRNA]; NR1I2 protein affects the reaction [hyperforin results in increased expression of CYP2C9 mRNA]; NR1I2 protein promotes the reaction [hyperforin results in increased abundance of Lipids]
hyperforin binds to NR1I2 protein
hyperforin results in increased activity of NR1I2 protein

PMID:14600250 PMID:15630458 PMID:15856409 PMID:20079722 PMID:26187274 More...

NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658

G

cytochrome p450 oxidoreductase

increases expression

hyperforin results in increased expression of POR mRNA

NCBI chr12:20,951,058...20,999,198
Ensembl chr12:20,951,058...20,999,245

G

solute carrier family 22 member 1

decreases expression
multiple interactions

hyperforin results in decreased expression of SLC22A1 protein
[NR1I2 protein co-treated with hyperforin] results in decreased expression of SLC22A1 mRNA; [NR1I2 protein results in increased susceptibility to hyperforin] which results in decreased expression of SLC22A1 mRNA; hyperforin promotes the reaction [NR1I2 protein results in decreased expression of SLC22A1 mRNA]

NCBI chr 1:48,076,657...48,103,679
Ensembl chr 1:48,076,666...48,103,678

G

transient receptor potential cation channel, subfamily C, member 6

multiple interactions

hyperforin inhibits the reaction [Propofol results in decreased expression of TRPC6 protein]

NCBI chr 8:5,759,387...5,864,000
Ensembl chr 8:5,758,935...5,828,092

G

UDP glucuronosyltransferase family 1 member A1

increases expression

hyperforin results in increased expression of UGT1A1 mRNA

NCBI chr 9:88,801,344...88,808,465
Ensembl chr 9:88,713,184...88,808,465

G

X-linked inhibitor of apoptosis

decreases expression

hyperforin results in decreased expression of XIAP protein

NCBI chr X:120,890,537...120,938,413
Ensembl chr X:120,897,907...120,934,700

irofulven

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ERCC excision repair 6, chromatin remodeling factor

increases response to substance

ERCC6 mutant form results in increased susceptibility to irofulven

NCBI chr16:7,764,983...7,835,587
Ensembl chr16:7,765,013...7,835,587

G

glutathione-disulfide reductase

decreases activity

irofulven results in decreased activity of GSR protein

NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661

ketamine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily A member 1

increases expression

Ketamine results in increased expression of ABCA1 mRNA

NCBI chr 5:67,678,267...67,801,162